<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004655.pub3" GROUP_ID="ENDOC" ID="859202121712041229" MERGED_FROM="" MODIFIED="2018-03-14 12:02:56 +0000" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="R_I_05_3" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.2"><COVER_SHEET MODIFIED="2018-03-14 12:02:55 +0000" MODIFIED_BY="Gudrun Paletta"><TITLE MODIFIED="2018-02-05 02:05:01 +0100" MODIFIED_BY="[Empty name]">Oral vitamin B<SUB>12</SUB> versus intramuscular vitamin B<SUB>12</SUB> for vitamin B<SUB>12</SUB> deficiency</TITLE><CONTACT MODIFIED="2018-03-14 12:02:55 +0000" MODIFIED_BY="Gudrun Paletta"><PERSON ID="z1803121500291624892809442408009" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Tong Hua</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Dean of Graduate Campus</POSITION><EMAIL_1>thliu@vip.163.com</EMAIL_1><MOBILE_PHONE>+8613801020306</MOBILE_PHONE><ADDRESS><DEPARTMENT>Graduate Campus</DEPARTMENT><ORGANISATION>Beijing University of Chinese Medicine</ORGANISATION><ADDRESS_1>North Third Ring Road No. 11 School range</ADDRESS_1><ADDRESS_2>ChaoYang District</ADDRESS_2><CITY>Beijing</CITY><ZIP>100029</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+8601064287545</PHONE_1><FAX_1>+8601064287545</FAX_1></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2018-03-14 12:02:55 +0000" MODIFIED_BY="Gudrun Paletta"><PERSON ID="z1506091239502974556757221150153" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Haiyan</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><EMAIL_1>lanyatou1986@126.com</EMAIL_1><MOBILE_PHONE>+8618610113023</MOBILE_PHONE><ADDRESS><DEPARTMENT>Institute of Traditional Chinese Medicine</DEPARTMENT><ORGANISATION>Beijing University of Chinese Medicine</ORGANISATION><ADDRESS_1>No. 11, North Third Ring Road, School range</ADDRESS_1><ADDRESS_2>ChaoYang District</ADDRESS_2><CITY>Beijing</CITY><ZIP>100029</ZIP><REGION>Beijing</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+8601064287545</PHONE_1><FAX_1>+8601064287545</FAX_1></ADDRESS></PERSON><PERSON ID="z1506111538556454234368463041181" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Linyi</FIRST_NAME><LAST_NAME>Li</LAST_NAME><EMAIL_1>lilinyi8567@163.com</EMAIL_1><MOBILE_PHONE>+8615010355968</MOBILE_PHONE><ADDRESS><DEPARTMENT>Key Laboratory of Upper Airway Dysfunction-related Cardiovascular Diseases</DEPARTMENT><ORGANISATION>Beijing Anzhen Hospital&#65292;Capital Medical University&#65292;Beijing Institute of Heart&#65292;Lung and Blood Vessel Diseases</ORGANISATION><ADDRESS_1>Anzhen Road  No. 2</ADDRESS_1><ADDRESS_2>ChaoYang District</ADDRESS_2><CITY>Beijing</CITY><ZIP>100029</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+8601064287545</PHONE_1><FAX_1>+8601064287545</FAX_1></ADDRESS></PERSON><PERSON ID="z1506111542411235296932640792607" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ling Ling</FIRST_NAME><LAST_NAME>Qin</LAST_NAME><EMAIL_1>15201484725@126.com</EMAIL_1><MOBILE_PHONE>+8615201484725</MOBILE_PHONE><ADDRESS><DEPARTMENT>Dongfang Hospital Affiliated to Beijing University of Chinese Medicine</DEPARTMENT><ORGANISATION>Beijing University of Chinese Medicine</ORGANISATION><ADDRESS_1>North Third Ring Road No. 11 School range</ADDRESS_1><ADDRESS_2>ChaoYang District</ADDRESS_2><CITY>Beijing</CITY><ZIP>100029</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+8601064287545</PHONE_1><FAX_1>+8601064287545</FAX_1></ADDRESS></PERSON><PERSON ID="z1506111544553556265305726008038" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yanan</FIRST_NAME><LAST_NAME>Song</LAST_NAME><EMAIL_1>tcmsong@126.com</EMAIL_1><MOBILE_PHONE>+8618010091989</MOBILE_PHONE><ADDRESS><DEPARTMENT>Dongfang Hospital Affiliated to Beijing University of Chinese Medicine</DEPARTMENT><ORGANISATION>Beijing University of Chinese Medicine</ORGANISATION><ADDRESS_1>North Third Ring Road No. 11 School range</ADDRESS_1><ADDRESS_2>ChaoYang District</ADDRESS_2><CITY>Beijing</CITY><ZIP>100029</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+8601064287545</PHONE_1><FAX_1>+8601064287545</FAX_1></ADDRESS></PERSON><PERSON ID="14759" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Josep</FIRST_NAME><LAST_NAME>Vidal-Alaball</LAST_NAME><POSITION>General Practitioner and PhD student</POSITION><EMAIL_1>josep.vidal@gmail.com</EMAIL_1><URL>https://icscatalunyacentral.wordpress.com/</URL><MOBILE_PHONE>0034659354025</MOBILE_PHONE><ADDRESS><DEPARTMENT>Gerència Territorial Catalunya Central</DEPARTMENT><ORGANISATION>Catalan Health Institute</ORGANISATION><ADDRESS_1>Carrer Pica d'Estats, 36</ADDRESS_1><CITY>St Fruitós de Bages</CITY><ZIP>08272</ZIP><REGION>Barcelona</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+ 34 6930040</PHONE_1></ADDRESS></PERSON><PERSON ID="z1803121500291624892809442408009" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Tong Hua</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Dean of Graduate Campus</POSITION><EMAIL_1>thliu@vip.163.com</EMAIL_1><MOBILE_PHONE>+8613801020306</MOBILE_PHONE><ADDRESS><DEPARTMENT>Graduate Campus</DEPARTMENT><ORGANISATION>Beijing University of Chinese Medicine</ORGANISATION><ADDRESS_1>North Third Ring Road No. 11 School range</ADDRESS_1><ADDRESS_2>ChaoYang District</ADDRESS_2><CITY>Beijing</CITY><ZIP>100029</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+8601064287545</PHONE_1><FAX_1>+8601064287545</FAX_1></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2018-03-14 12:02:55 +0000" MODIFIED_BY="Gudrun Paletta"><UP_TO_DATE><DATE DAY="17" MONTH="7" YEAR="2017"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="17" MONTH="7" YEAR="2017"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="17" MONTH="7" YEAR="2019"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/><REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/><LAST_CITATION_ISSUE ISSUE="3" YEAR="2018"/></DATES><WHATS_NEW MODIFIED="2017-10-30 13:04:54 +0100" MODIFIED_BY="[Empty name]"><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-10-30 13:04:54 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="26" MONTH="10" YEAR="2017"/><DESCRIPTION><P>In this update we included one additional trial.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-10-30 13:04:36 +0100" MODIFIED_BY="[Empty name]"><DATE DAY="26" MONTH="10" YEAR="2017"/><DESCRIPTION><P>In this update we included a total of three trials.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2008-11-05 20:51:24 +0100" MODIFIED_BY="Gudrun Paletta"/><SOURCES_OF_SUPPORT MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter"><INTERNAL_SOURCES MODIFIED="2013-07-16 11:02:57 +0200" MODIFIED_BY="[Empty name]"><SOURCE><NAME>Department of General Practice, Wales College of Medicine, Cardiff University</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION/></SOURCE><SOURCE><NAME>National Public Health Service for Wales, Wales</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION/></SOURCE><SOURCE MODIFIED="2013-07-16 11:02:57 +0200" MODIFIED_BY="[Empty name]"><NAME>Department of General Practice and Elderly Care Medicine, VU University Medical Center, Amsterdam</NAME><COUNTRY CODE="NL">Netherlands</COUNTRY><DESCRIPTION/></SOURCE></INTERNAL_SOURCES><EXTERNAL_SOURCES/></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2018-03-14 13:00:35 +0100" MODIFIED_BY="[Empty name]"><SUMMARY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TITLE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]">Oral vitamin B<SUB>12</SUB> compared with intramuscular vitamin B<SUB>12</SUB> for vitamin B<SUB>12</SUB> deficiency</TITLE><SUMMARY_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P><B>Review question</B></P><P>Does oral vitamin B<SUB>12</SUB> have similar effects as intramuscular injections of vitamin B<SUB>12 </SUB>for people with vitamin B<SUB>12</SUB> deficiency?</P><P><B>Background</B></P><P>Vitamin B<SUB>12</SUB> (cobalamin) is necessary for basic body functions, such as the growth and development of red blood cells and the nervous system. Vitamin B<SUB>12</SUB> deficiency (a lack of vitamin B<SUB>12</SUB>) is very common. Many factors contribute to vitamin B<SUB>12</SUB> deficiency, such as age, blood disease, vegetarian diet, indigestion, use of drugs, as well as poor nutrition. Doctors are more likely to give vitamin B<SUB>12</SUB> using injections into the muscle (intramuscular injection) because they may be unaware of the option to use oral vitamin B<SUB>12</SUB> or uncertain about how well it works.</P><P><B>Study characteristics</B></P><P>We found three randomised controlled studies (clinical studies where people are randomly put into one of two or more treatment groups). The studies randomised 153 participants (74 participants to oral vitamin B<SUB>12</SUB> and 79 participants to intramuscular vitamin B<SUB>12</SUB>). Treatment duration and follow-up ranged between three and four months. The mean age of participants ranged from 39 to 72 years.</P><P><B>Key results</B></P><P>Two studies used 1000 &#956;g/day oral vitamin B<SUB>12 </SUB>and showed no relevant difference to intramuscularly applied vitamin B<SUB>12</SUB> with regard to vitamin B<SUB>12 </SUB>blood levels. One trial used 2000 &#956;g/day vitamin B<SUB>12 </SUB>and showed higher vitamin B<SUB>12</SUB> blood levels in favour of oral vitamin B<SUB>12</SUB>. Two studies reported side effects. One study stated that no treatment-related side effects were seen in both the oral and intramuscular vitamin B<SUB>12</SUB> groups. One study reported that 2 of 30 participants in the oral vitamin B<SUB>12 </SUB>group left the trial early due to side effects. Orally taken vitamin B<SUB>12</SUB> showed lower treatment-associated costs than intramuscular vitamin B<SUB>12 </SUB>in one trial. No study reported on clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency (e.g. fatigue, depression, neurological complications), health-related quality of life, or acceptability of the treatment scheme.</P><P><B>Quality of the evidence</B></P><P>The overall quality of the evidence was low or very low, mainly due to the small number of included studies and the low numbers of participants in these studies.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><ABS_BACKGROUND MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Vitamin B<SUB>12</SUB> deficiency is common, and the incidence increases with age. Most people with vitamin B<SUB>12</SUB> deficiency are treated in primary care with intramuscular (IM) vitamin B<SUB>12</SUB>. Doctors may not be prescribing oral vitamin B<SUB>12</SUB> formulations because they may be unaware of this option or have concerns regarding its effectiveness.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>To assess the effects of oral vitamin B<SUB>12</SUB> versus intramuscular vitamin B<SUB>12</SUB> for vitamin B<SUB>12</SUB> deficiency.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We searched CENTRAL, MEDLINE, Embase, and LILACS, as well as the WHO ICTRP and ClinicalTrials.gov. The latest search date was 17 July 2017. We applied no language restrictions. We also contacted authors of relevant trials to enquire about other published or unpublished studies and ongoing trials.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2016-08-16 03:30:41 +0200" MODIFIED_BY="[Empty name]"><P>Randomised controlled trials (RCTs) comparing the effect of oral versus IM vitamin B<SUB>12</SUB> for vitamin B<SUB>12</SUB> deficiency.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We used standard methodological procedures expected by Cochrane. Our primary outcomes were serum vitamin B<SUB>12</SUB> levels, clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency, and adverse events. Secondary outcomes were health-related quality of life, acceptability to patients, haemoglobin and mean corpuscular volume, total homocysteine and serum methylmalonic acid levels, and socioeconomic effects. We used GRADE to assess the quality of the evidence for important outcomes. We did not perform meta-analyses due to the small number of included trials and substantial clinical heterogeneity.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Three RCTs met our inclusion criteria. The trials randomised 153 participants (74 participants to oral vitamin B<SUB>12</SUB> and 79 participants to IM vitamin B<SUB>12</SUB>). Treatment duration and follow-up ranged between three and four months. The mean age of participants ranged from 38.6 to 72 years. The treatment frequency and daily dose of vitamin B<SUB>12 </SUB>in the oral and IM groups varied among trials. Only one trial had low or unclear risk of bias across all domains and outcome measures. Two trials reported data for serum vitamin B<SUB>12</SUB> levels. The overall quality of evidence for this outcome was low due to serious imprecision (low number of trials and participants). In two trials employing 1000 &#956;g/day oral vitamin B<SUB>12</SUB>, there was no clinically relevant difference in vitamin B<SUB>12</SUB> levels when compared with IM vitamin B<SUB>12</SUB>. One trial used 2000 &#956;g/day vitamin B<SUB>12 </SUB>and demonstrated a mean difference of 680 pg/mL (95% confidence interval 392.7 to 967.3) in favour of oral vitamin B<SUB>12</SUB>. Two trials reported data on adverse events (very low-quality evidence due to risk of performance bias, detection bias, and serious imprecision). One trial stated that no treatment-related adverse events were seen in both the oral and IM vitamin B<SUB>12</SUB> groups. One trial reported that 2 of 30 participants (6.7%) in the oral vitamin B<SUB>12 </SUB>group left the trial early due to adverse events. Orally taken vitamin B<SUB>12</SUB> showed lower treatment-associated costs than IM vitamin B<SUB>12 </SUB>in one trial (low-quality evidence due to serious imprecision). No trial reported on clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency, health-related quality of life, or acceptability of the treatment scheme.</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Low quality evidence shows oral and IM vitamin B<SUB>12 </SUB>having similar effects in terms of normalising serum vitamin B<SUB>12</SUB> levels, but oral treatment costs less. We found very low-quality evidence that oral vitamin B<SUB>12</SUB> appears as safe as IM vitamin B<SUB>12</SUB>. Further trials should conduct better randomisation and blinding procedures, recruit more participants, and provide adequate reporting. Future trials should also measure important outcomes such as the clinical signs and symptoms of vitamin B<SUB>12 </SUB>deficiency, health related-quality of life, socioeconomic effects, and report adverse events adequately, preferably in a primary care setting.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2018-02-26 13:28:36 +0100" MODIFIED_BY="[Empty name]"><BACKGROUND MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><CONDITION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Vitamins are a group of substances required for effective human metabolism. Under normal circumstances it is essential that they are present in a person's diet because, with few exceptions, the human body is unable to manufacture them. Vitamins often work together with enzymes, cofactors, and other substances. Vitamin B<SUB>12</SUB> (cobalamin) is necessary for the development of red blood cells, growth, and nervous system maintenance. The only dietary sources of vitamin B<SUB>12</SUB> are animal products, such as eggs, fish, and meats. Daily requirements are age-related: the recommended dietary amounts for adults and infants are 1.5 µg and 0.4 µg, respectively (<LINK REF="REF-Anonymous-1991" TYPE="REFERENCE">Anonymous 1991</LINK>; <LINK REF="REF-FAO_x002f_WHO-1988" TYPE="REFERENCE">FAO/WHO 1988</LINK>).</P><P>Vitamin B<SUB>12</SUB> is absorbed in the terminal ileum. This absorption is almost entirely dependent upon the intrinsic factor, a glycoprotein secreted by parietal cells situated in the mucosa of the stomach. Intrinsic factor binds to vitamin B<SUB>12</SUB>, and the complex is transported across the cell membrane bound to another glycoprotein called transcobalamin. The most common cause of vitamin B<SUB>12</SUB> deficiency is autoimmune pernicious anaemia, a condition that carries an increased risk of gastric cancer. In pernicious anaemia, absorption is impaired due to intrinsic factor deficiency arising from autoimmune destruction of parietal cells. Other common causes of vitamin B<SUB>12</SUB> deficiency include gastrectomy, ileal resection, pancreatic insufficiency, and malabsorption syndromes including Crohn's disease and celiac disease. Other less common causes of vitamin B<SUB>12</SUB> deficiency include use of drugs such as biguanides (metformin), antacids (proton pump inhibitors and H<SUB>2</SUB> receptors antagonists), aminoglycoside, antibiotics and colchicines, and rarely, malabsorption due to gastrointestinal bacterial overgrowth, congenital defects (e.g. birth transcobalamin deficiency), and infestation. Pure nutritional deficiency is rare and usually occurs only in strict vegans (<LINK REF="REF-Watanabe-2013" TYPE="REFERENCE">Watanabe 2013</LINK>). In some cases, vitamin B<SUB>12</SUB> deficiency can be a risk factor for cardiovascular disease (<LINK REF="REF-Pawlak-2015" TYPE="REFERENCE">Pawlak 2015</LINK>). It is recommended that vegetarians take vitamin B<SUB>12</SUB> supplements to prevent vitamin B<SUB>12</SUB> deficiency (<LINK REF="REF-Pawlak-2013" TYPE="REFERENCE">Pawlak 2013</LINK>).</P><P>The prevalence of vitamin B<SUB>12</SUB> deficiency varies among countries, and manifests in population groups when the vitamin B<SUB>12 </SUB>demand increases whilst the intake remains unchanged or is reduced, such as in infants, pregnant women, and the elderly. The incidence of vitamin B<SUB>12</SUB> deficiency increases with age, probably due to the fact that elderly people are more likely to suffer from food-cobalamin malabsorption. This malabsorption is caused primarily by gastric atrophy but also by chronic carriage of <I>Helicobacter pylori</I>, long-term ingestion of metformin and proton pump inhibitors, and increased chances of having gastric surgery (<LINK REF="REF-Andres-2004" TYPE="REFERENCE">Andres 2004</LINK>; <LINK REF="REF-De-Jager-2010" TYPE="REFERENCE">De Jager 2010</LINK>; <LINK REF="REF-Lam-2013" TYPE="REFERENCE">Lam 2013</LINK>). The prevalence of vitamin B<SUB>12</SUB> deficiency in the elderly varies substantially in different studies, with reported figures between 1.5% and 15% (<LINK REF="REF-Brito-2015" TYPE="REFERENCE">Brito 2015</LINK>; <LINK REF="REF-Clarke-2004" TYPE="REFERENCE">Clarke 2004</LINK>; <LINK REF="REF-Figlin-2003" TYPE="REFERENCE">Figlin 2003</LINK>; <LINK REF="REF-MacFarlane-2011" TYPE="REFERENCE">MacFarlane 2011</LINK>; <LINK REF="REF-Pennypacker-1992" TYPE="REFERENCE">Pennypacker 1992</LINK>; <LINK REF="REF-Rajan-2002" TYPE="REFERENCE">Rajan 2002</LINK>; <LINK REF="REF-van-Walraven-1999" TYPE="REFERENCE">van Walraven 1999</LINK>). The differences may be due to inconsistent diagnostic criteria for vitamin B<SUB>12</SUB> deficiency.</P><P>As well as varying with age, prevalence also varies with gender and ethnic group: elderly men are more likely to have low vitamin B<SUB>12</SUB> levels than elderly women. The prevalence of vitamin B<SUB>12</SUB> deficiency is higher in Europe than in the USA (<LINK REF="REF-Lindenbaum-1994" TYPE="REFERENCE">Lindenbaum 1994</LINK>; <LINK REF="REF-Pennypacker-1992" TYPE="REFERENCE">Pennypacker 1992</LINK>). African and Asian countries have the highest rates of vitamin B<SUB>12</SUB> deficiency, for example both Kenyan and Indian schoolchildren have a rate above 70%, as well as Indian adults (<LINK REF="REF-Allen-2009" TYPE="REFERENCE">Allen 2009</LINK>).</P><P>Vitamin B<SUB>12 </SUB>is a cofactor to methylation, which facilitates DNA synthesis and haemopoiesis and maintains neurological function (<LINK REF="REF-Green-2013" TYPE="REFERENCE">Green 2013</LINK>). Vitamin B<SUB>12</SUB> deficiency can cause serious clinical symptoms such as megaloblastic anaemia, paralysis, dementia, fatigue, and mood disturbance. If left untreated, serious neurological and neuropsychiatric complications can occur. Vitamin B<SUB>12</SUB> deficiency has also been linked with an increased risk of myocardial infarction and stroke. A recent study reported that there is a relationship between vitamin B<SUB>12</SUB> deficiency and delirium in elderly patients undergoing cardiac surgery (<LINK REF="REF-Schroll-2015" TYPE="REFERENCE">Schroll 2015</LINK>).</P><P>The diagnosis of vitamin B<SUB>12</SUB> deficiency is based mainly on blood measurements of serum vitamin B<SUB>12</SUB> level less than 200 pg/mL (148 pmol/L), complemented with second-line tests including total homocysteine and methylmalonic acid levels, which are metabolic indicators of vitamin B<SUB>12</SUB> deficiency. Studies have indicated that an estimated 20% of people can present with neuropsychiatric symptoms in the absence of haematological abnormalities (<LINK REF="REF-Quadros--2010" TYPE="REFERENCE">Quadros 2010</LINK>).</P></CONDITION><INTERVENTION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Vitamin B<SUB>12</SUB> was first isolated in its cyano-form in 1948 (<LINK REF="REF-Rickes-1948" TYPE="REFERENCE">Rickes 1948</LINK>; <LINK REF="REF-Smith-1948" TYPE="REFERENCE">Smith 1948</LINK>), and is now widely used for the treatment of vitamin B<SUB>12</SUB> deficiency. Most vitamin B<SUB>12</SUB>-deficient individuals in the UK and other countries are treated with intramuscular vitamin B<SUB>12</SUB>, and vitamin B<SUB>12</SUB> replacement has been traditionally administered intramuscularly. Intramuscular vitamin B<SUB>12</SUB> can be administered in two different forms: cyanocobalamin and hydroxocobalamin. In some countries hydroxocobalamin has completely replaced cyanocobalamin as first choice for vitamin B<SUB>12</SUB> therapy because it is retained in the body longer and can be administered at intervals of up to three months (<LINK REF="REF-BNF-2004" TYPE="REFERENCE">BNF 2004</LINK>).</P><P>Several case control and case series studies have since suggested that oral vitamin B<SUB>12 </SUB>has an equal efficacy and safety as intramuscular vitamin B<SUB>12 </SUB>(<LINK REF="REF-Andres-2010" TYPE="REFERENCE">Andres 2010</LINK>; <LINK REF="REF-Bahadir-2015" TYPE="REFERENCE">Bahadir 2015</LINK>; <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="REF-Castelli-2011" TYPE="REFERENCE">Castelli 2011</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). However, despite its availability in most countries and its very safe track record, vitamin B<SUB>12</SUB> is rarely prescribed in the oral form. Two exceptions to this are in Canada and Sweden, where in the year 2000 oral vitamin B<SUB>12</SUB> accounted for 73% of the total vitamin B<SUB>12</SUB> prescribed (<LINK REF="REF-Nilsson-2005" TYPE="REFERENCE">Nilsson 2005</LINK>). Possible reasons for doctors not prescribing oral formulations may include a lack of awareness of this option or concerns regarding unpredictable absorption (<LINK REF="REF-Graham-2007" TYPE="REFERENCE">Graham 2007</LINK>; <LINK REF="REF-Lederle-1998" TYPE="REFERENCE">Lederle 1998</LINK>). In the UK, oral vitamin B<SUB>12</SUB> is currently not available on National Health Service (NHS) prescription in high-dose formulations.<BR/></P><SUBSECTION><HEADING LEVEL="5">Adverse effects of the intervention</HEADING><P>Intramuscular vitamin B<SUB>12</SUB> can cause significant pain, especially in thin people (<LINK REF="REF-Elia-1998" TYPE="REFERENCE">Elia 1998</LINK>). While serious adverse reactions are rare, injections can be dangerous in anticoagulated individuals. No adverse effects of oral administration have been reported (<LINK REF="REF-Andres-2010" TYPE="REFERENCE">Andres 2010</LINK>).</P></SUBSECTION></INTERVENTION><THEORY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>The mechanism for the intramuscular route is most probably that vitamin B<SUB>12</SUB> can be absorbed and transported by fluid diffusion. Doctors traditionally believed that the main reasons of vitamin B<SUB>12</SUB> deficiency were that the patients were lacking intrinsic factor or had gastrointestinal disease or bowel resection. Gastrointestinal absorption barriers of vitamin B<SUB>12</SUB> can be avoided by intramuscular injection.</P><P>The mechanism for the oral route is most probably that free vitamin B<SUB>12</SUB> can be absorbed both passively (without binding to intrinsic factor) as well as actively (following binding to intrinsic factor) in the terminal ileum. Passive diffusion accounts for 1.2% of total absorption with a bioavailability unaffected in people with pernicious anaemia or gastro-duodenal surgical resection (<LINK REF="REF-Berlin-1968" TYPE="REFERENCE">Berlin 1968</LINK>; <LINK REF="REF-Berlin-1978" TYPE="REFERENCE">Berlin 1978</LINK>). High doses of oral vitamin B<SUB>12</SUB> (e.g. 1000 µg daily) may be able to produce adequate absorption of vitamin B<SUB>12</SUB> even in the presence of intrinsic factor deficiency, and therefore may be an alternative to the intramuscular route for many people.</P></THEORY><IMPORTANCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>This review is an update of the Cochrane Review comparing oral with intramuscular vitamin B<SUB>12</SUB> published in 2005 (<LINK REF="REF-Vidal_x002d_Alaball-2005" TYPE="REFERENCE">Vidal-Alaball 2005</LINK>). The original review suggested that high doses of oral vitamin B<SUB>12</SUB> may be as effective as intramuscular administration in obtaining short-term haematological and neurological responses in vitamin B<SUB>12</SUB>-deficient people.</P><P>Intramuscular injections are a "considerable source of work" for healthcare professionals, mainly general practitioners and community nurses (<LINK REF="REF-Middleton-1985" TYPE="REFERENCE">Middleton 1985</LINK>). There is little difference in the cost of oral versus intramuscular therapy when the medication alone is considered. However, intramuscular administration often involves a special trip to a health facility or a home visit by a health professional to administer the injection (<LINK REF="STD-Houle-2014" TYPE="STUDY">Houle 2014</LINK>). Oral treatment could therefore save considerable health service resources.</P><P>A recent Canadian study estimated that converting people aged over 65 years on B<SUB>12</SUB> replacement from the intramuscular to oral form could save CAD 13,975,883, even if no additional physician visits were billed for people receiving intramuscular therapy. A total of CAD 8,444,346 could be saved from reduced administration costs alone over five years (<LINK REF="STD-Houle-2014" TYPE="STUDY">Houle 2014</LINK>).</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>To assess the effects of oral vitamin B<SUB>12</SUB> versus intramuscular vitamin B<SUB>12</SUB> for vitamin B<SUB>12</SUB> deficiency.</P></OBJECTIVES><METHODS MODIFIED="2018-02-26 13:20:55 +0100" MODIFIED_BY="[Empty name]"><SELECTION_CRITERIA MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><CRIT_STUDIES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We included randomised controlled clinical trials examining the use of oral versus intramuscular vitamin B<SUB>12</SUB> to treat vitamin B<SUB>12</SUB> deficiency. We regarded a two-week treatment duration as minimum trial duration.</P><P>We excluded trials examining the role of vitamin B<SUB>12</SUB> in the prevention of cardiovascular diseases, because the dose of vitamin B<SUB>12</SUB> used in those trials may be different from the dose used to treat vitamin B<SUB>12</SUB> deficiency, and the majority of participants included in such trials are not vitamin B<SUB>12</SUB> deficient.</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Trial participants with vitamin B<SUB>12</SUB> deficiency, meeting criteria for vitamin B<SUB>12</SUB> replacement therapy.</P><SUBSECTION><HEADING LEVEL="4">Diagnostic criteria for vitamin B<SUB>12</SUB> deficiency</HEADING><P>We used a cut-off point of below 200 pg/mL (below 148 pmol/L) as a threshold serum level for vitamin B<SUB>12</SUB> deficiency.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Excluded populations</HEADING><P>We excluded trials with participants with:</P><UL><LI>primary folate deficiency, because the concomitant use of folate might confound the metabolic outcome measures;</LI><LI>end-stage renal disease or on haemodialysis, because renal disease might confound the metabolic outcome measures.</LI></UL></SUBSECTION></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="4">Intervention</HEADING><UL><LI>Oral vitamin B<SUB>12</SUB></LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Comparator</HEADING><UL><LI>Intramuscular vitamin B<SUB>12</SUB></LI></UL><P>Where a trial included multiple arms, we included any arm that met the inclusion criteria of our review.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Minimum duration of intervention</HEADING><P>We defined minimum trial duration as two weeks, and only included trials with interventions that lasted longer than two weeks. We planned to list trials with less than two weeks duration in an Additional table but not include them in the analyses, however we did not encounter any such trials.</P></SUBSECTION></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We analysed the following outcomes in the review, but did not use them as a basis for including or excluding studies. Had we found relevant trials not reporting any of our primary or secondary outcomes, we would have included the trials but we would not have evaluated them in detail.</P><CRIT_OUTCOMES_PRIMARY MODIFIED="2018-02-05 03:19:59 +0100" MODIFIED_BY="[Empty name]"><OL><LI>Serum vitamin B<SUB>12</SUB> levels.</LI><LI>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency.</LI><LI>Adverse events.</LI></OL></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><OL><LI>Health-related quality of life.</LI><LI>Acceptability.</LI><LI>Haemoglobin and mean corpuscular volume (MCV).</LI><LI>Total homocysteine and serum methylmalonic acid levels.</LI><LI>Socioeconomic effects.</LI></OL><SUBSECTION><HEADING LEVEL="4">Method and timing of outcome measurement</HEADING><P>All outcomes required a minimum of two weeks follow-up from baseline. We categorised the time points of outcome measurement as short term (two weeks to three months), medium term (three to nine months), and long term (more than nine months).</P><UL><LI>Serum vitamin B<SUB>12</SUB> levels: measured at the end of study (mean values and whether these were normalised; normalised serum vitamin B<SUB>12</SUB> was defined as &gt; 240 pg/mL).</LI><LI>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency: e.g. fatigue, macrocytosis, pancytopenia, depression, tiredness, paralysis, dementia psychosis measured at short, medium, and long term.</LI><LI>Adverse events: e.g. itching, exanthema, chills, fever, hot flushes, nausea, dizziness, and anaphylaxis and measured at short, medium, and long term.</LI><LI>Health-related quality of life: evaluated by a validated instrument such as 36-item Short Form Health Survey (SF-36) and measured at short, medium, and long term.</LI><LI>Acceptability: acceptability to participants as defined by trial authors and measured at short, medium, and long term.</LI><LI>Haemoglobin and MCV: measured at short, medium, and long term.</LI><LI>Total homocysteine and serum methylmalonic acid levels: measured at short, medium, and long term.</LI><LI>Socioeconomic effects: refer to costs and measured at short, medium, and long term.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Summary of findings</HEADING><P>We presented a 'Summary of findings' table reporting the following outcomes, listed according to priority.</P><OL><LI>Serum vitamin B<SUB>12</SUB> levels.</LI><LI>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency (such as depression, tiredness, paralysis, or dementia).</LI><LI>Adverse events.</LI><LI>Health-related quality of life.</LI><LI>Acceptability.</LI><LI>Socioeconomic effects.</LI></OL></SUBSECTION></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2018-02-26 13:20:55 +0100" MODIFIED_BY="[Empty name]"><ELECTRONIC_SEARCHES MODIFIED="2018-02-26 13:20:55 +0100" MODIFIED_BY="[Empty name]"><P>We searched the following sources between the specified dates and placed no restrictions on the language of publication.</P><UL><LI>Cochrane Library</LI><UL><LI>Cochrane Central Register of Controlled Trials (CENTRAL) (2005 to issue 6 of 12, June 2017; search date 17 July 2017)</LI><LI>Database of Abstracts of Reviews of Effects (DARE) (2005 to issue 2 of 4, April 2015; search date 22 July 2015)</LI><LI>Health Technology Assessment Database (2005 to issue 2 of 4, April 2015; search date 22 July 2015)</LI><LI>NHS Economic Evaluation Database (2005 to issue 2 of 4, April 2015; search date 22 July 2015)</LI></UL><LI>Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &lt;1946 to present&gt; (1 December 2014 to 17 July 2017)</LI><LI>Embase &lt;1974 to 2016 November 09&gt; (2004 Week 48 to 10 November 2016)</LI><LI>LILACS (Latin American and Caribbean Health Sciences Literature database) (&lt;last update 27 October 2006&gt;) (Inception to 10 November 2016)</LI><LI>ClinicalTrials.gov (<A HREF="http://ClinicalTrials.gov">clinicaltrials.gov</A>) (search date 17 July 2017)</LI><LI>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>) (search date 10 November 2016)</LI></UL><P>We continuously applied a MEDLINE (via Ovid) email alert service established by the Cochrane Metabolic and Endocrine Disorders (CMED) Group to identify newly published studies using the same search strategy as described for MEDLINE (for details on search strategies, see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). </P></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, systematic reviews, meta-analyses, and health technology assessment reports. In addition, we contacted authors of included trials to identify any further published or unpublished trials and ongoing trials that we may have missed.</P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><STUDY_SELECTION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>For this update, two review authors (HYW and THL) independently scanned the abstract or title, or both, of every record retrieved, to determine which studies should assessed further. We investigated the full-text articles of all potentially relevant articles. Any discrepancies were resolved through consensus or by recourse to a third review author (YNS). If we could not resolve a disagreement, we categorised the study as a 'study awaiting classification' and contacted the study authors for clarification. We have presented an adapted PRISMA flow diagram to show the process of study selection (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>).</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>For trials that fulfilled the inclusion criteria, two review authors (LYL and LLQ) independently extracted key participant and intervention characteristics and outcomes. We included key characteristics of the trials, such as trial design, setting, sample size, population, and how outcomes were defined or collected in the trials. In addition, we also collected data on the method of diagnosing vitamin B<SUB>12</SUB> deficiency, any pre-existing treatment and titration period.</P><P>We reported data on efficacy outcomes and adverse events using standard data extraction templates supplied by the CMED Group (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>; <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>; <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>). Any disagreements were resolved by discussion or, if required, by consultation with a third review author (YNS).</P><P>We provided information about potentially relevant ongoing studies, including the trial identifier number, in the <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> and in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> (matrix of trial endpoints (publications and trial documents)). We attempted to find the protocol for each included study and reported primary, secondary, and other outcomes in comparison with data in publications in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> .</P><P>We emailed all authors of the included trials to enquire whether they would be willing to answer questions regarding their trials. <LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK> shows the results of this survey. Thereafter, when required, we sought relevant missing information on the trial from the primary author(s) of the article.</P><SUBSECTION><HEADING LEVEL="4">Dealing with duplicate and companion publications</HEADING><P>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we planned to maximise the information yield by collating all available data and using the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, or multiple reports of a primary trial as secondary references under the study ID of the included or excluded trial.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Data from clinical trial registers</HEADING><P>In cases where the data of included trials were available as study results in clinical trial registers such as ClinicalTrials.gov or similar sources, we planned to make full use of this information and used this to extract data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information was available, we added this trial to the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK> table.</P></SUBSECTION></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Two review authors (LYL and LLQ) independently assessed the risk of bias of each included study. Any disagreements were resolved by consensus, or by consultation with a third review author (YNS). If adequate information was not available from the publications or trial protocols, we contacted trial authors for missing data on 'Risk of bias' items. We contacted authors of included studies but not due to inadequate information on 'Risk of bias' items.</P><P>Using the Cochrane 'Risk of bias' assessment tool (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), we judged 'Risk of bias' criteria as having either low, high, or unclear risk, evaluating the individual bias items described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> according to the criteria and associated categorisations contained therein (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).<BR/></P><SUBSECTION><HEADING LEVEL="5">Random sequence generation (selection bias due to inadequate generation of a randomised sequence) - assessment at trial level</HEADING><P>For each included trial we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P><UL><LI>Low risk of bias: the sequence generation was achieved using computer-generated random numbers or a random numbers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial. We considered the use of the minimisation technique as equivalent to being random.</LI><LI>Unclear risk of bias: insufficient information about the sequence generation process.</LI><LI>High risk of bias: the sequence generation method was non-random or quasi-random (e.g. sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgement of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; allocation by availability of the intervention).</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment) - assessment at trial level</HEADING><P>For each included trial we described the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment.</P><UL><LI>Low risk of bias: central allocation (including telephone, interactive voice-recorder, web-based, and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.</LI><LI>Unclear risk of bias: insufficient information about the allocation concealment.</LI><LI>High risk of bias: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by participants and personnel during the trial) - assessment at outcome level</HEADING><P>We evaluated the risk of detection bias separately for each outcome (<LINK REF="REF-Hr_x00f3_bjartsson-2013" TYPE="REFERENCE">Hróbjartsson 2013</LINK>). We noted whether endpoints were self reported, investigator assessed, or adjudicated outcome measures (see below).</P><UL><LI>Low risk of bias: blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.</LI><LI>Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial did not address this outcome.</LI><LI>High risk of bias: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment) - assessment at outcome level</HEADING><P>We evaluated the risk of detection bias separately for each outcome (<LINK REF="REF-Hr_x00f3_bjartsson-2013" TYPE="REFERENCE">Hróbjartsson 2013</LINK>). We noted whether endpoints were self reported, investigator assessed, or adjudicated outcome measures (see below).</P><UL><LI>Low risk of bias: blinding of outcome assessment ensured, and unlikely that the blinding could have been broken; no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding.</LI><LI>Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome.</LI><LI>High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Incomplete outcome data (attrition bias due to amount, nature, or handling of incomplete outcome data) - assessment at outcome level</HEADING><P>For each included trial and for each outcome, we described the completeness of data, including attrition and exclusions from the analysis. We stated whether trials reported attrition and exclusions, and the number of participants included in the analysis at each stage (compared with the number of randomised participants per intervention/comparator groups). We also noted if trials reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to outcomes. We considered the implications of missing outcome data per outcome, such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms).</P><UL><LI>Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes not enough to have a clinically relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data.</LI><LI>Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias; the trial did not address this outcome.</LI><LI>High risk of bias: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as-treated' or similar analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Selective reporting (reporting bias due to selective outcome reporting) - assessment at trial level</HEADING><P>We assessed outcome reporting bias by integrating the results of <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> 'Matrix of trial endpoints (publications and trial documents)' (<LINK REF="REF-Boutron-2014" TYPE="REFERENCE">Boutron 2014</LINK>; <LINK REF="REF-Mathieu-2009" TYPE="REFERENCE">Mathieu 2009</LINK>), with those of <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> 'High risk of outcome reporting bias according to Outcome Reporting Bias In Trials (ORBIT) classification' (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>). This analysis formed the basis for the judgement of selective reporting.<BR/></P><UL><LI>Low risk of bias: the trial protocol was available, and all of the trial's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way; the study protocol is not available, but it was clear that the published reports include all expected outcomes (ORBIT classification).</LI><LI>Unclear risk of bias: insufficient information about selective reporting.</LI><LI>High risk of bias: not all of the trial's prespecified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the trial report fails to include results for a key outcome that would be expected to have been reported for such a trial (ORBIT classification).</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Other bias (bias due to problems not covered elsewhere) - assessment at trial level</HEADING><UL><LI>Low risk of bias: the trial appeared to be free of other sources of bias.</LI><LI>Unclear risk of bias: insufficient information to assess whether an important risk of bias existed; insufficient rationale or evidence that an identified problem introduced bias.</LI><LI>High risk of bias: had a potential source of bias related to the specific trial design used; has been claimed to have been fraudulent; had some other serious problem.</LI></UL><P>We have presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.</P><P>We distinguished between self reported, investigator-assessed, and adjudicated outcome measures.</P><P>We defined the following outcomes as self reported.</P><UL><LI>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency, as reported by participants.</LI><LI>Health-related quality of life.</LI><LI>Acceptability.</LI><LI>Adverse events, as measured by participants.</LI></UL><P>We defined the following outcomes as investigator-assessed outcome.</P><UL><LI>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency, as reported by study personnel.</LI><LI>Haemoglobin and MCV.</LI><LI>Total homocysteine and serum methylmalonic acid levels.</LI><LI>Adverse events, as measured by study personnel.</LI><LI>Socioeconomic effects.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Summary assessment of risk of bias</HEADING><P><B>Risk of bias for a trial across outcomes:</B> some 'Risk of bias' domains like selection bias (sequence generation and allocation sequence concealment) affect the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, we planned to mark all endpoints investigated in the associated trial as high risk. Otherwise, we would not perform a summary assessment of the risk of bias across all outcomes for a trial.</P><P><B>Risk of bias for an outcome within a trial and across domains:</B> we planned to assess the risk of bias for an outcome measure including all of the entries relevant to that outcome (i.e. both trial-level entries and outcome-specific entries). We considered low risk of bias to denote a low risk of bias for all key domains; unclear risk to denote an unclear risk of bias for one or more key domains; and high risk to denote a high risk of bias for one or more key domains.</P><P><B>Risk of bias for an outcome across trials and across domains:</B> these are our main summary assessments which we would incorporate in our judgements about the quality of evidence in the 'Summary of findings table 1'. We defined outcomes as at low risk of bias when most information came from trials at low risk of bias,; unclear risk when most information came from trials at low or unclear risk of bias; and high risk when a sufficient proportion of information came from trials at high risk of bias.</P></SUBSECTION></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2018-02-14 12:40:08 +0100" MODIFIED_BY="[Empty name]"><P>When at least two studies were available for a comparison and a given outcome, we expressed dichotomous data as odds ratio (OR) or risk ratio (RR) with 95% confidence interval (CI). We expressed continuous data as mean difference (MD) with 95% CIs. We planned to express time-to-event data as hazard ratio (HR) with 95% CI, however we did not encounter this type of data.</P></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We planned to take into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials, and multiple observations for the same outcome.</P><P>If more than one comparison from the same trial was eligible for inclusion in the same meta-analysis, we would either combine groups to create a single pair-wise comparison or appropriately reduce the sample size so that the same participants did not contribute multiple times (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>If possible, we obtained missing data from trial authors and carefully evaluated important numerical data such as screened, randomly assigned participants as well as intention-to-treat, as-treated, and per-protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow-up, withdrawals) and critically appraised issues concerning missing data and imputation methods (e.g. last observation carried forward).</P><P>In trials where the standard deviation (SD) of the outcome was not available at follow-up or could not be re-created, we standardised by the average of the pooled baseline SD from those trials in which this information was reported.</P><P>Where trials did not report means and SDs for outcomes, and we could not obtain the needed information from trial authors, we imputed these values by estimating the mean and variance from the median, range, and the size of the sample (<LINK REF="REF-Hozo-2005" TYPE="REFERENCE">Hozo 2005</LINK>).</P><P>We planned to investigate the impact of imputation on meta-analyses by performing sensitivity analyses, and we reported per outcome which trials were included with imputed SDs. However, we eventually did not perform meta-analysis due to significant clinical heterogeneity.</P></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We planned to identify heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of &#945; = 0.1. In view of the low power of this test, we also planned to consider the I² statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>); an I² statistic of 75% or more indicates a considerable level of heterogeneity (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P><P>When we found heterogeneity, we attempted to determine potential reasons for it by examining individual study and subgroup characteristics.</P><P>In the event of substantial clinical, methodological, or statistical heterogeneity, we did not report study results as meta-analytically pooled effect estimates.</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Had we included 10 or more trials investigating a particular outcome, we would have used funnel plots to assess small-study effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias, therefore we would have interpreted the results carefully (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Unless good evidence showed homogeneous effects across studies, we primarily summarised data at low risk of bias using a random-effects model (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). We interpreted random-effects meta-analyses with consideration of the whole distribution of effects, ideally by presenting a prediction interval (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). A prediction interval specifies a predicted range for the true treatment effect in an individual study (<LINK REF="REF-Riley-2011" TYPE="REFERENCE">Riley 2011</LINK>). For rare events such as event rates below 1%, we used Peto's odds ratio method, provided there was no substantial imbalance between intervention and comparator group sizes, and intervention effects were not exceptionally large. In addition, we also performed statistical analyses according to the statistical guidelines presented in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P><P>If in the future adequate data become available, we will use this method of analysis.<BR/></P><SUBSECTION><HEADING LEVEL="4">Quality of the evidence</HEADING><P>We rated the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results<I>. </I>Two review authors (HYW and THL) independently rated the quality of the evidence for each outcome. We have presented a summary of the evidence in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome, and rating of overall confidence in effect estimates for each outcome.</P><P>We selected six important outcomes and created the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> based on methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>, by means of the table editor in Review Manager 5, including <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK> 'Checklist to aid consistency and reproducibility of GRADE assessments' to help with standardisation of the 'Summary of findings' table (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>; <LINK REF="REF-Meader-2014" TYPE="REFERENCE">Meader 2014</LINK>; <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>; <LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). As meta-analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary.</P></SUBSECTION></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out the following subgroup analysis with investigation of interactions. If in the future adequate data become available, we will conduct this method of analysis.<BR/></P><UL><LI>Newly diagnosed participants.</LI><LI>Participants already established on intramuscular treatment.</LI><LI>Participants over 65 years of age.</LI><LI>Participants who have had stomach or small bowel resection.</LI><LI>Vegetarians.</LI><LI>Participants taking anti-ulcer medication over long periods.</LI><LI>Participants with dementia.</LI><LI>Participants with AIDS.</LI></UL></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following.</P><UL><LI>Published trials.</LI><LI>Taking into account risk of bias, as specified in the <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> section.</LI><LI>Very long or large trials, to establish the extent to which they dominate the results.</LI><LI>Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country.</LI></UL><P>We also planned to test the robustness of results by repeating the analyses using different measures of effect size (RR, OR, etc.) and different statistical models (fixed-effect and random-effects models). If in the future adequate data become available, we will conduct this method of analysis.</P></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2018-02-26 13:28:36 +0100" MODIFIED_BY="[Empty name]"><STUDY_DESCRIPTION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>For a detailed description of trials, see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>, <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies,</LINK> <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>, and '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P><SEARCH_RESULTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>The updated search identified 2328 records, of which 39 full-text articles and records were identified for further examination. We excluded the publications/records based on their titles or abstracts, because they did not meet the inclusion criteria or were not relevant to the question under study (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> ). After screening the full texts of the selected publications/records, six trials met the inclusion criteria with two ongoing trials (<LINK REF="STD-EUCTR-2009_x002d_014468_x002d_20_x002d_AT" TYPE="STUDY">EUCTR 2009-014468-20-AT</LINK>; <LINK REF="STD-NCT01476007" TYPE="STUDY">NCT01476007</LINK>), and one trial awaiting assessment (<LINK REF="STD-Ashok-2011" TYPE="STUDY">Ashok 2011</LINK>). As two trials, <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> and <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>, have been included in the previous version of this review (<LINK REF="REF-Vidal_x002d_Alaball-2005" TYPE="REFERENCE">Vidal-Alaball 2005</LINK>), a total of three trials were included in this update (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>; <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). We sought additional information from the trial authors but did not receive a response.</P><SUBSECTION><HEADING LEVEL="4">Handsearching</HEADING><P>Searching the bibliographies of the selected articles and other relevant publications did not identify additional trials.</P></SUBSECTION></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>A detailed description of the characteristics of included trials is presented elsewhere (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>). The following is a succinct overview.</P><SUBSECTION><HEADING LEVEL="4">Trial design</HEADING><P>All included trials were parallel randomised controlled trials. Two trials had a superiority design (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>), and one trial was a non-inferiority study (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). One trial was multicentre study conducted at four centres (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). Two trials had an open-label design (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>), and one trial did not report on blinding conditions (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</P><P>One trial was conducted between 2009 to 2010 (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). Two trials were performed more than 10 years ago: from 1993 to 1996 in <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> and from 1999 to 2003 in <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>. The treatment duration and follow-up period ranged between three and four months (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). No trial was terminated early.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Settings</HEADING><P>The three trials were conducted in South India (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>), Turkey (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>), and the USA (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). Recruiting and treating participants occurred in tertiary care hospitals and ambulatory care centres.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Participants</HEADING><P>For detailed characteristics of participants, please refer to <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P><P>The trials randomised a total of 153 participants. Ten participants in <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> left the trial early, and five participants in <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> were judged to have primary folate deficiency rather than cobalamin deficiency and were excluded from the final analysis. Eleven participants in <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> left the study early due to adverse events (n = 2), loss to follow-up (n = 6), lack of subjective improvement (n = 2), and "expired" (n = 1). Finally, 142 participants completed the three trials (92.8%).</P><P>Only one trial reported the ethnicity of participants (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</P><P>No trials reported the duration of vitamin B<SUB>12</SUB> deficiency.</P><SUBSECTION><HEADING LEVEL="5">Diagnostic criteria</HEADING><P>Two trials included people with a serum vitamin B<SUB>12</SUB> level of less than 160 pg/mL (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>); the other trial used a threshold of less than 200 pg/mL.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Inclusion and exclusion criteria</HEADING><P>Two trials excluded people with folate deficiency (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). One trial excluded people who were already on vitamin B<SUB>12</SUB> supplements (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). The details of inclusion and exclusion criteria in individual trials are outlined in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Gender distribution</HEADING><P>We could ascertain the overall gender distribution of the 153 participants: 56% were male and 44% were female.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Age distribution</HEADING><P>The mean age of participants ranged from 38.6 to 72 years. <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> investigated participants with a mean age of 72 years for the oral group and 71 years for the intramuscular (IM) group. <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> investigated participants with a mean age of 60 years for the oral group and 64 years for the IM group. <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> investigated a younger population group with an average age of 38.6 in the oral vitamin B<SUB>12</SUB> group and 44.3 in the IM vitamin B<SUB>12</SUB> group.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Comorbidities</HEADING><P>In one trial 74% of participants had conditions that could have been associated with malabsorption from the gut (including seven people with pernicious anaemia and three people with ileal resection), although it appears that people with inflammatory bowel disease and celiac disease were not included (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). One trial included 50% of participants with conditions affecting the ileum that could have been associated with malabsorption from the gut (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). It appears that people with inflammatory bowel disease and celiac disease were not included. One trial did not report the comorbidities of participants (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Interventions</HEADING><P>All trials compared oral vitamin B<SUB>12</SUB> with IM vitamin B<SUB>12 </SUB>(see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P><P>The total daily dosage of vitamin B<SUB>12</SUB> in the oral group was 1000 &#956;g, in <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> and <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>, or 2000 &#956;g, in <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>. <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> used cyanocobalamin mixed with 20 mL fruit juice, while <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> used vitamin B<SUB>12</SUB> tablets. <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> did not report details about the administration of oral vitamin B<SUB>12</SUB>. The type of vitamin B<SUB>12</SUB> injection used in two studies was cyanocobalamin (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>), while the third study did not report this information. However, the treatment duration, frequency, and total dose of vitamin B<SUB>12</SUB> varied between trials.</P><UL><LI><LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> used the same dose of vitamin B<SUB>12</SUB> and the same frequency of treatment in both arms. The total dose of vitamin B<SUB>12</SUB> in the three-month trial was 15 mg in each group.</LI><LI><LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> used a substantially higher daily and total dose in the oral group (2000 µg per day for four months; total dose 240 mg), while for the IM group, the total dose of vitamin B<SUB>12</SUB> was merely 9 mg over 90 days.</LI><LI><LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> used 1000 &#956;g of vitamin B<SUB>12</SUB> daily for 3 months in the oral group (total dose 90 mg) and a total dose of 15 mg vitamin B<SUB>12 </SUB>over 9 weeks in the IM group.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Outcomes</HEADING><P>One trial explicitly stated a primary endpoint in the abstract (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). The total number of measured outcomes in the included trials ranged from two to nine. All trials described definitions of outcomes in the publications, if applicable (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P><SUBSECTION><HEADING LEVEL="5">Trials reporting our primary outcomes</HEADING><P>Serum vitamin B<SUB>12</SUB>: two trials measured the mean values of serum vitamin B<SUB>12 </SUB>(<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). Two trials reported the number of participants with normalisation of serum vitamin B<SUB>12</SUB> deficiency (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>; <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>), but the definitions used varied between trials.</P><UL><LI>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency: no trials reported this outcome. <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> stated measuring the "improvements in signs and symptoms of anemia", however the authors did not report data for this outcome (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</LI><LI>Adverse events: two trials reported on adverse events (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>).</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Trials reporting our secondary outcomes</HEADING><UL><LI>Health-related quality of life: no trial reported this outcome.</LI><LI>Acceptability: no trial reported this outcome.</LI><LI>Haemoglobiln and MCV: <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> (60 participants) reported haemoglobin levels. Two trials (93 participants) reported MCV (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</LI><LI>Total homocysteine and serum methylmalonic acid levels: one trial (33 participants) reported this outcome (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</LI><LI>Socioeconomic effects: <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> (60 participants) reported on the tolerability of medication (assessed by a haematologist and patient interviews), and costs, which the trial authors assessed using cost of the trial drug and the injections.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Other outcomes reported in the included trials</HEADING><UL><LI>Mini-Mental State Examination.</LI><LI>Neurologic symptoms.</LI><LI>Serum holotranscobalamin levels.</LI><LI>Serum folate.</LI><LI>Parietal and intrinsic factor antibodies.</LI><LI>Serum anti-intrinsic factor antibodies.</LI></UL></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Funding and conflicts of interest in trials</HEADING><P>No funding information was reported.<BR/></P></SUBSECTION></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We excluded 31 full-text records. The most common reason for exclusion was a non-randomised trial design, or the comparison or population in the trial did not meet intervention criteria. Reasons for exclusion of studies are detailed in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P><SUBSECTION><HEADING LEVEL="3">Ongoing studies</HEADING><P>We found two ongoing randomised controlled trials. One trial with an estimated sample size of 320 was registered on ClinicalTrials.gov and was expected to be completed by the year 2017 (<LINK REF="STD-NCT01476007" TYPE="STUDY">NCT01476007</LINK>). This trial compared oral vitamin B<SUB>12</SUB> with IM vitamin B<SUB>12</SUB> in elderly people (65 years and above) with vitamin deficiency (defined as serum vitamin B<SUB>12</SUB> less than 179 pg/mL). Another trial was registered on the European Clinical Trials Register in 2010 (<LINK REF="STD-EUCTR-2009_x002d_014468_x002d_20_x002d_AT" TYPE="STUDY">EUCTR 2009-014468-20-AT</LINK>). This trial compared sublingual vitamin B<SUB>12</SUB> supplementation with IM vitamin B<SUB>12</SUB> supplementation after gastric bypass surgery. No further details were reported.</P></SUBSECTION></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>For details on the risk of bias of the included studies see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P><P>For an overview of review authors' judgements about each 'Risk of bias' item for individual studies and across all studies see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P><ALLOCATION MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>We rated one trial as at low risk of bias for randomisation: <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> stated that they used a statistical package for randomisation. We rated the other two trials as at unclear risk of bias: <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> stated that participants were randomised using the block randomisation method, but did not state how the randomisation was performed. <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> did not report how the randomisation was conducted.</P><P>No trial reported adequate details of allocation concealment. Baseline characteristics were balanced between the two intervention groups for all included trials.</P></ALLOCATION><BLINDING MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Participants in two trials were not blinded, as the design was open-label randomised controlled trial (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). The other trial did not report sufficient information about blinding procedures (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). However, we judged the performance bias and detection bias as low risk due to the objective nature of outcome measurements other than the outcome adverse events, which was judged as high risk.</P></BLINDING><EXCLUSIONS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>In <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>, 38 participants were randomised, but five participants (13%) were excluded from the final analysis because they were judged to have primary folate deficiency rather than vitamin B<SUB>12</SUB> deficiency. As the missing data were not likely to impact the effect, we assessed attrition bias as low risk.</P><P>In <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>, 70 participants were enrolled in the study, but 10 (14%) were excluded because of failure to appear at follow-up. The final analysis included 26 participants in the oral group and 34 randomised to receive intramuscular treatment. The authors did not analyse data according to the intention-to-treat principle. We assessed the attrition bias as unclear risk.</P><P>In <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>, 60 participants were randomised, but 11 participants (18.3%) left the study early due to various reasons: eight participants dropped out from the oral vitamin B<SUB>12</SUB> group due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2); three participants from the IM vitamin B<SUB>12</SUB> group left the study early due to expired (n = 1) and loss to follow-up (n = 2). The attrition rate was high, and the missing data were likely to impact the estimate of effects. We therefore assessed attrition bias as high risk.</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>No trial reported any information about their protocols, therefore it was difficult to judge what outcomes were measured but not reported (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). We assessed reporting bias at trial level as unclear risk. Three outcomes predefined in our protocol were not reported by any of the included trials: i) clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency; ii) health-related quality of life; and iii) acceptability. Details about which outcomes were reported by the original trials can be found in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>We did not identify other obvious bias in the three included trials and rated this domain as low risk.</P><SUBSECTION><HEADING LEVEL="4">Sample size calculation</HEADING><P>Only one trial provided a sample size calculation (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). The calculation was based on the assumption that an equal response of 90% between oral and IM vitamin B<SUB>12</SUB> groups and a non-inferiority margin of 25% (alpha = 0.25, 1 - beta = 0.80). The expected sample size in each group was 23.</P></SUBSECTION></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2018-02-26 13:28:36 +0100" MODIFIED_BY="[Empty name]"><SUBSECTION><HEADING LEVEL="3">Baseline characteristics</HEADING><P>For details of baseline characteristics, see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. Due to the small number of included trials and substantial clinical heterogeneity, instead of pooling the data we primarily presented the extracted data in the forest plots and reported the results descriptively.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Oral vitamin B<SUB>12</SUB> versus intramuscular vitamin B<SUB>12</SUB></HEADING><SUBSECTION><HEADING LEVEL="4">Primary outcomes</HEADING><SUBSECTION><HEADING LEVEL="5">Serum vitamin B<SUB>12</SUB> levels</HEADING><P>Two trials reported serum vitamin B<SUB>12</SUB> levels (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). For a detailed description of the interventions, see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. The overall quality of the evidence was low due to serious imprecision.</P><P>One trial used an oral or IM vitamin B<SUB>12</SUB> dose of 1000 &#956;g per day and a total dose of 15 mg within three months of treatment (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). The oral treatment compared with the IM treatment showed a mean difference (MD) of -11.7 pg/mL (95% confidence interval (CI) -29.5 to 6.1; P = 0.20; 60 participants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). After three months, the mean serum vitamin B<SUB>12</SUB> concentration in the oral vitamin B<SUB>12</SUB> group was 213.8 pg/mL compared with 225.5 pg/mL in the IM group (normal value: above 300 pg/mL).</P><P>Another trial compared an oral vitamin B<SUB>12</SUB> dose of 2000 &#956;g per day for 120 days (total dose 240 mg) with an IM vitamin B<SUB>12</SUB> dose of 1000 &#956;g per day over a period of 90 days (total dose 9 mg) (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). The oral compared with the IM treatment showed an MD of 680 pg/mL (95% CI 392.7 to 967.3; P &lt; 0.001; 33 participants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>), in favour of oral vitamin B<SUB>12</SUB>. At four months, the mean serum vitamin B<SUB>12</SUB> concentration in the oral vitamin B<SUB>12</SUB> group was 1005 pg/mL (18/18 participants &gt; 300 pg/mL) compared with 325 pg/mL (7/14 participants &gt; 300 pg/mL) in the IM group.</P><P>When the normalisation of serum vitamin B<SUB>12</SUB> was defined as greater than 200 pg/mL, differences between the oral vitamin B<SUB>12</SUB> and IM vitamin B<SUB>12</SUB> groups depended on the dose of vitamin B<SUB>12 </SUB>(<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>)</P><P><LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> reported the number of participants achieving normalisation of the serum vitamin B<SUB>12</SUB> level, defined as &#8805; 200 pg/mL (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). The trial employed an oral vitamin B<SUB>12</SUB> dose of 1000 &#956;g per day for three months (total dose 90 mg) and an IM vitamin B<SUB>12</SUB> dose of 1000 &#956;g (total dose of 15 mg within three months of treatment). A total of 27/30 in the IM vitamin B<SUB>12 </SUB>group (90%) and 20/30 in the oral vitamin B<SUB>12 </SUB>group (66.7%) achieved this target; although fewer participants in the oral vitamin B<SUB>12</SUB> group achieved the target, the difference was statistically non-significant (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). However, <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> used a much higher dose of oral vitamin B<SUB>12 </SUB>(240 mg in total) versus a much lower dose of IM vitamin B<SUB>12 </SUB>(total dose 9 mg). A total of 10/14 in the IM vitamin B<SUB>12 </SUB>group (71.4%) and 18/18 in the oral vitamin B<SUB>12 </SUB>group (100%) achieved this target; although more participants in the oral vitamin B<SUB>12</SUB> group achieved the target, the difference was statistically non-significant (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Clinical signs and symptoms</HEADING><P>No trial reported this outcome.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Adverse effects</HEADING><P>Two trials reported this outcome (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>). The overall quality of the evidence was very low due to risk of performance and detection bias and serious imprecision.</P><P>One trial reported no adverse events in both the oral and IM vitamin B<SUB>12</SUB> groups (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). The other trial reported that two participants in the oral vitamin B<SUB>12 </SUB>group left the trial early due to adverse events (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>).</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Secondary outcomes</HEADING><SUBSECTION><HEADING LEVEL="5">Health-related quality of life</HEADING><P>No trial reported this outcome.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Acceptability to patients</HEADING><P>No trial reported this outcome.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Haemoglobin and mean corpuscular volume</HEADING><P>Only one trial reported on haemoglobin measurements (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). There was no substantial difference between the oral and intramuscular supplementation of vitamin B<SUB>12</SUB>: MD 0.1 g/dL, 95% CI -0.30 to 0.50; P = 0.63; 60 participants; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.</P><P>Two trials reported on MCV measurements (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>; <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>). One trial showed an MD between oral and IM vitamin B<SUB>12</SUB> treatment of 0.20 fL (95% CI -1.84 to 2.24; P = 0.85; 60 participants; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). The other trial reported an MD of -1.00 fL (95% CI -5.80 to 3.80; P = 0.68; 33 participants; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Total homocysteine and serum methylmalonic acid levels</HEADING><P>One trial reported on homocysteine measurements. The MD between oral and IM vitamin B<SUB>12</SUB> treatment was -1.60 &#956;mol/L (95% CI -4.50 to 1.30; P = 0.28; 33 participants; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) (<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</P><P>This trial also investigated serum methylmalonic acid. The MD between oral and IM vitamin B<SUB>12</SUB> treatment was -96 nmol/L (95% CI -200.76 to 8.76; P = 0.07; 33 participants; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="5">Socioeconomic effects</HEADING><P>Only one trial reported the costs of the two administration schemes of vitamin B<SUB>12</SUB> (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). The quality of evidence was low due to serious imprecision. The results demonstrated that the costs per treatment were USD 80 per person in the group taking oral vitamin B<SUB>12</SUB> compared to USD 220 per person in the group using IM vitamin B<SUB>12</SUB> (P &lt; 0.001). The trial authors did not report which economic analysis was performed.</P></SUBSECTION></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Subgroup analyses</HEADING><P>We did not perform subgroup analyses due to the small number of included trials and substantial variety among characteristics of population, interventions, and outcome measurements of the included trials. The dosage of orally taken vitamin B<SUB>12</SUB> might be a potential prognostic factor influencing the treatment effect.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Sensitivity analyses</HEADING><P>Due to substantial clinical heterogeneity and the low number of included trials, we did not pool the data and did not conduct the planned sensitivity analyses.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Assessment of reporting bias</HEADING><P>We did not draw funnel plots due to the limited number of included trials.</P></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><SUMMARY_OF_RESULTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Low-quality evidence showed that both oral vitamin B<SUB>12</SUB> and IM vitamin B<SUB>12</SUB> can improve serum vitamin B<SUB>12</SUB> levels for people with vitamin B<SUB>12</SUB> deficiency. However, the dosage of oral vitamin B<SUB>12</SUB> might be a clinical factor to affect this outcome. When oral vitamin B<SUB>12</SUB> was used in higher dosages (2000 &#956;g/day with a total dose of 240 mg), the serum vitamin B<SUB>12</SUB> levels were much higher (on average 680 pg/mL higher) than that in the IM vitamin B<SUB>12</SUB> group (1000 &#956;g/day with a total dose of 9 mg). Similarly, the number of participants achieving normalisation of vitamin B<SUB>12</SUB> levels also depended on the dose of vitamin B<SUB>12</SUB> and was higher in the oral vitamin B<SUB>12</SUB> group when treated with 2000 &#956;g/day. We found no substantial differences were between the intervention groups for adverse events. There were also no substantial differences between intervention groups in haemoglobin and MCV levels, total homocysteine, and serum methylmalonic acid levels. The costs of treatment in the oral vitamin B<SUB>12</SUB> group were lower than those in the IM vitamin B<SUB>12</SUB> group. The overall quality of the evidence was low or very low. Two trials are still ongoing, and the full report of one trial was not published. It is likely that the estimate of the effect may change when data from these trials are included.</P><P>Most of the dietary vitamin B<SUB>12</SUB> is absorbed actively via intrinsic factor, and passive diffusion accounts for about 1% of vitamin B<SUB>12</SUB> absorption. Therefore, an oral dose of 1000 µg daily should be sufficient to meet the dietary daily amount recommended (<LINK REF="STD-Kolber-2014" TYPE="STUDY">Kolber 2014</LINK>). This theory also explains why higher oral vitamin B<SUB>12</SUB> can achieve similar effects as intramuscular vitamin B<SUB>12</SUB>. A previous study confirmed that oral therapy can be effective even in intrinsic factor-lacking and gastrointestinal-disabled people (<LINK REF="REF-Andres-2008" TYPE="REFERENCE">Andres 2008</LINK>; <LINK REF="REF-Andres-2009" TYPE="REFERENCE">Andres 2009</LINK>; <LINK REF="REF-Andres-2010" TYPE="REFERENCE">Andres 2010</LINK>). Some of the participants in our included trials, such as those with atrophic gastritis, also showed improvements after oral vitamin B<SUB>12</SUB> therapy. However, these results must be interpreted with caution due to the small number of participants and trials.</P></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>More elderly males with vitamin B<SUB>12</SUB> deficiency were included in the current review. A higher prevalence of vitamin B<SUB>12</SUB> deficiency amongst the elderly is documented (<LINK REF="REF-Stabler-2013" TYPE="REFERENCE">Stabler 2013</LINK>), and vitamin B<SUB>12 </SUB>deficiency occurs more frequently in elderly men than in elderly women. None of the trials was conducted in a primary care setting, where most people with vitamin B<SUB>12</SUB> deficiencies are treated; this makes generalisation of the results more difficult. It should be noted that one ongoing trial recruiting participants from 23 primary settings may add important information (<LINK REF="STD-NCT01476007" TYPE="STUDY">NCT01476007</LINK>). Another factor affecting generalisation is that the three included trials used strict and numerous exclusion criteria.</P><P>Secondly, for IM interventions, there are two main kinds of vitamin B<SUB>12</SUB> injections: cyanocobalamin and hydroxocobalamin. Only cyanocobalamin was used in the studies included in this review. It should be noted that the bioavailability of injectable hydroxocobalamin preparations is much higher than the water solution preparations of cyanocobalamin (<LINK REF="REF-Boddy-1968" TYPE="REFERENCE">Boddy 1968</LINK>; <LINK REF="REF-Glass-1961" TYPE="REFERENCE">Glass 1961</LINK>).</P><P>Thirdly, the number of outcomes reported was limited, and several important outcomes were not measured in the original trials, such as clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency after the intervention. Notably, using the normalisation of serum levels of vitamin B<SUB>12</SUB> and its metabolites to reflect the response to treatment is not enough. There may be no direct correlation between normalisation of serum vitamin B<SUB>12</SUB> and improvement of clinical symptoms (<LINK REF="REF-Andres-2009" TYPE="REFERENCE">Andres 2009</LINK>; <LINK REF="REF-Hall-1977" TYPE="REFERENCE">Hall 1977</LINK>).</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Using GRADE, we judged the quality of the evidence in the review to be low or very low. This was mainly due to serious imprecision, inconsistency between trials, and high risk of bias for some domains of included trials. The body of evidence did not allow robust conclusions regarding the objectives of our review. We could include only three trials with small numbers of participants. Missing data (attrition rates ranged from 13.2% to 18.3%) may also have affected some effects estimates. The inconsistency between trials was associated with substantial clinical heterogeneity.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>The incomplete correspondence with trial authors and the missing results of the two ongoing trials limit our evidence base. We failed to obtain the full text of one trial (<LINK REF="STD-Ashok-2011" TYPE="STUDY">Ashok 2011</LINK>), in which 38 participants were recruited. The definitions of vitamin B<SUB>12</SUB> deficiency used in this review differed from that defined in our protocol, in which we used a more strict threshold to define vitamin B<SUB>12</SUB> deficiency in order to reflect common practice.</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>This is an update of a previous review (<LINK REF="REF-Vidal_x002d_Alaball-2005" TYPE="REFERENCE">Vidal-Alaball 2005</LINK>). We included one additional trial in this update (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>), but the conclusions remain unchanged. We identified no recent systematic review or health technology assessment report on oral versus IM vitamin B<SUB>12 </SUB>supplement for vitamin B<SUB>12</SUB> deficiency.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><IMPLICATIONS_PRACTICE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Questions about the use of oral or intramuscular (IM) vitamin B<SUB>12 </SUB>have been debated by doctors for nearly 50 years, and a conclusive answer is still lacking. Low-quality evidence indicates that an oral dose of 1000 &#956;g/day vitamin B<SUB>12</SUB> works similarly to IM vitamin B<SUB>12</SUB> in restoring serum B<SUB>12</SUB> levels and acquiring haematological responses in people who are vitamin B<SUB>12 </SUB>deficient. An oral dose of 2000 &#956;g/day vitamin B<SUB>12</SUB> might be more effective than IM vitamin B<SUB>12</SUB> .</P><P>Adverse events were rare, and low-quality evidence indicates that oral vitamin B<SUB>12 </SUB>costs less than IM vitamin B<SUB>12</SUB> injections. No trial reported on clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency, health-related quality of life, or acceptability of the treatment scheme.</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>All of the trials included in our review had methodological shortcomings and an insufficient set of outcome data. Further trials should conduct better blinding procedures, recruit more participants, and provide adequate reporting. In addition, future trials should also measure important outcomes such as the clinical signs and symptoms of vitamin B<SUB>12 </SUB>deficiency, health-related quality of life, and socioeconomic effects. It is also important that the protocol considers adverse effects and that these are reported as part of the trial.</P><P>Future trials should be performed in primary care settings on participants without considering gender, ethnicity, age, and region. It is important for future research to include participants with poor absorption of oral vitamin B<SUB>12</SUB>, such as those with pernicious anaemia, gastrointestinal disease or resection. Considering that the diagnosis and treatment of vitamin B<SUB>12</SUB> deficiency is related to the metabolism of vitamin B<SUB>12</SUB>, more research should be conducted focusing on the absorption, distribution, metabolism, and excretion processes of vitamin B<SUB>12</SUB>.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><UL><LI>Christopher C Butler, Rebecca Cannings-John, Andrew Goringe, Kerry Hood, Andrew McCaddon, Ian McDowell, Alexandra Papaioannou, Johannes C van der Wouden, and Rianne Langeveld (original Cochrane Review).</LI><LI>The search strategies for this review update were designed and run by the CMED Group's Information Specialist, Maria-Inti Metzendorf.</LI><LI>We thank Ms Sai Zhao from Systematic Review Solution Ltd for being our methodology and reporting consultant.</LI></UL></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2018-03-14 13:00:35 +0100" MODIFIED_BY="[Empty name]"><P>HYW: none known</P><P>LYL: none known.</P><P>LLQ: none known.</P><P>YNS: none known.</P><P>JVA: none known.</P><P>THL: none known.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2018-03-14 13:00:27 +0100" MODIFIED_BY="[Empty name]"><P>All review authors read and approved the final review draft.</P><P>Hai Yan Wang (HYW): trial selection, data analysis, data interpretation, quality of evidence assessment, and review writing.</P><P>Linyi Li (LYL): data extraction and 'Risk of bias' assessment.</P><P>Ling Ling Qin (LLQ): data extraction and 'Risk of bias' assessment.</P><P>Yanan Song (YNS): trial selection, 'Risk of bias' assessment, data analysis, data interpretation, and review update.</P><P>Josep Vidal-Alaball (JVA): protocol draft, search strategy development, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review draft, and future review updates.</P><P>Tong Hua Liu (THL): trial selection, data analysis, quality of evidence assessment, and data interpretation.<BR/></P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>The review authors' team changed for this update: Christopher C Butler, Rebecca Cannings-John, Andrew Goringe, Kerry Hood, Andrew McCaddon, Ian McDowell, Alexandra Papaioannou, Johannes C van der Wouden, and Rianne Langeveld are no longer review authors.</P><P>Since the last publication of this review (Issue 3, 2005), multiple changes such as new methods and other standards were introduced, leading to a complete renewal of this Cochrane Review. We have revised the search strategies for this review update. The following sections have also been changed.</P><UL><LI>We used a cut-off point below 200 pg/mL (below 148 pmol/L) as a threshold serum level for vitamin B<SUB>12</SUB> deficiency to better differentiate vitamin B<SUB>12</SUB> deficiency from borderline deficiency.</LI><LI>Types of outcomes: we added the section 'Method and timing of outcome measurement' to define each outcome and group the timing of outcome measurement.</LI><LI>Types of outcomes: we added a 'Summary of findings' table.</LI><LI>We updated the 'Assessment of risk of bias of included studies' section to provide further details about our judgements.</LI><LI>We revised the 'Data extraction and management' section by specifying data items we planned to extract; adding two sections: 'Unit of analysis issues' and ' Dealing with missing data'; and other minor amendments.</LI></UL></PRO_REV_DIFF><PUBLIC_NOTES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>We included a total of three trials in this update (one additional trial compared to the first published version in 2005).</P></PUBLIC_NOTES></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2018-03-14 12:02:56 +0000" MODIFIED_BY="Gudrun Paletta">
<STUDIES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bolaman-2003" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Bolaman 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T</AU>
<TI>Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>12</NO>
<PG>3124-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775059"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzminski-1998" MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" NAME="Kuzminski 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J</AU>
<TI>Effective treatment of cobalamin deficiency with oral cobalamin</TI>
<SO>Blood</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>4</NO>
<PG>1191-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775064"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775063"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saraswathy-2012" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Saraswathy 2012" YEAR="2012">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saraswathy AR, Dutta A, Simon EG, Chacko A</AU>
<TI>Randomized open label trial comparing efficacy of oral versus intramuscular vitamin B12 supplementation for treatment of vitamin B12 deficiency</TI>
<SO>Gastroenterology</SO>
<YR>2012</YR>
<VL>142</VL>
<NO>5 Suppl 1</NO>
<PG>S216</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4242069"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775113"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aguilar-2004" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Aguilar 2004" YEAR="2004">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguilar Franco C</AU>
<TI>Subcutaneous administration of vitamin B12</TI>
<SO>Atencion Primaria</SO>
<YR>2004</YR>
<VL>34</VL>
<PG>509 (author reply 509)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775066"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775065"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andres-2005a" MODIFIED="2018-02-07 19:38:10 +0100" MODIFIED_BY="[Empty name]" NAME="Andres 2005a" YEAR="2005">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Affenberger S, Vinzio S, Noel E, Kaltenbach G, Schlienger JL</AU>
<TI>Cobalamin deficiencies in adults: update of etiologies, clinical manifestations and treatment</TI>
<SO>Revue de Medecine Interne</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>938-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779913"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779912"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andres-2005b" MODIFIED="2018-02-07 19:41:00 +0100" MODIFIED_BY="[Empty name]" NAME="Andres 2005b" YEAR="2005">
<REFERENCE MODIFIED="2018-02-07 19:41:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Noel E, Kaltenbach G</AU>
<TI>Usefulness of oral vitamin B12 therapy in vitamin B12 deficiency related to food-cobalamin malabsorption: Short and long-term outcome [1]</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2005</YR>
<VL>16</VL>
<PG>218</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779915"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779914"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andres-2011" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Andres 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Mecili M</AU>
<TI>Oral vitamin B12 therapy</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2011</YR>
<VL>18 Suppl 3</VL>
<PG>S196-8 (author reply S199)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775072"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775071"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andres-2012" MODIFIED="2018-02-07 19:39:19 +0100" MODIFIED_BY="[Empty name]" NAME="Andres 2012" YEAR="2012">
<REFERENCE MODIFIED="2018-02-07 19:39:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andres E</AU>
<TI>Oral cobalamin therapy: It may be perhaps time to propose international recommendations?</TI>
<SO>Presse Medicale</SO>
<YR>2012</YR>
<VL>41</VL>
<PG>895-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775074"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775073"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bharath-2015" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Bharath 2015" YEAR="2015">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bharath V, Hsia CC</AU>
<TI>Vitamin B12 deficiency presenting as pancytopenia with ring sideroblasts</TI>
<SO>Blood</SO>
<YR>2015</YR>
<VL>126</VL>
<PG>2255</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779917"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779916"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bharatwaj-2012" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Bharatwaj 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bharatwaj RS</AU>
<TI>The problem of cyanocobalamin defeciency in a developing country set-up and the possible solutions</TI>
<SO>Journal of Clinical and Diagnostic Research</SO>
<YR>2012</YR>
<VL>6</VL>
<PG>921-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775076"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775075"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butler-2006" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Butler 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butler CC, Vidal-Alaball J, Cannings-John R, McCaddon A, Hood K, Papaioannou A, et al</AU>
<TI>Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials</TI>
<SO>Family Practice</SO>
<YR>2006</YR>
<VL>23</VL>
<PG>279-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775078"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775077"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castelli-2010" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Castelli 2010" YEAR="2010">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Castelli MC, Friedman K, Sherry J, Brazzillo K, Genoble L, Bhargava P, et al</AU>
<TI>Comparing the efficacy and tolerability of a new daily oral vitamin B12 formulation and intermittent intramuscular vitamin B12 in normalizing low cobalamin levels: a randomized, open-label, parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2011</YR>
<VL>33</VL>
<PG>358-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779919"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castelli MC, Wong D, Friedman K, Bhargava P, Riley GM</AU>
<TI>Normalization of vitamin B12 (B12) levels achieved following 1000 mcg oral Eligen B12 therapy: a clinical study comparing the efficacy and safety of oral B12 therapy versus intramuscular (IM) therapy</TI>
<SO>FASEB Journal</SO>
<YR>2010</YR>
<VL>24</VL>
<PG>lb325</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779920"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779918"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emans-2013" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Emans 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emans ME, Gaillard CAJM, Pfister R, Tanck MW, Boekholdt SM, Wareham NJ, et al</AU>
<TI>Response to letter by Balta et al</TI>
<SO>International Journal of Cardiology</SO>
<YR>2013</YR>
<VL>169</VL>
<PG>89-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775080"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775079"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-EUCTR-2013_x002d_004835_x002d_60" MODIFIED="2018-02-19 13:45:23 +0100" MODIFIED_BY="[Empty name]" NAME="EUCTR 2013-004835-60" YEAR="">
<REFERENCE MODIFIED="2018-02-19 13:43:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Vitamin deficiencies and supplementation in morbidly obese</TI>
<SO>https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004835-60/NL</SO>
<YR>(accessed 6 December 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779922"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2018-02-19 13:44:38 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779921"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geisel-2005" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Geisel 2005" YEAR="2005">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geisel J, Schorr H, Bodis M, Isber S, Hubner U, Knapp JP, et al</AU>
<TI>The vegetarian lifestyle and DNA methylation</TI>
<SO>Clinical Chemistry &amp; Laboratory Medicine</SO>
<YR>2005</YR>
<VL>43</VL>
<PG>1164-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775082"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775081"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haffner-2016" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Haffner 2016" YEAR="2016">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haffner J</AU>
<TI>Oral treatment of vitamin B12 deficiency</TI>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>2016</YR>
<VL>136</VL>
<PG>108</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779924"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779923"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houle-2014" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Houle 2014" YEAR="2014">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Houle SK, Kolber MR, Chuck AW</AU>
<TI>Should vitamin B12 tablets be included in more Canadian drug formularies? An economic model of the cost-saving potential from increased utilisation of oral versus intramuscular vitamin B12 maintenance therapy for Alberta seniors (Provisional abstract)</TI>
<SO>BMJ Open</SO>
<YR>2014</YR>
<VL>4</VL>
<NO>5</NO>
<PG>e004501</PG>
<IDENTIFIERS MODIFIED="2016-08-24 11:33:50 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-08-24 11:33:50 +0200" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775084"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775083"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-ISRCTN22063938" MODIFIED="2018-02-19 13:49:32 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN22063938" YEAR="">
<REFERENCE MODIFIED="2018-02-19 13:49:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Cobalamin deficiency in primary care: a placebo-controlled, double-blind, randomized trial</TI>
<SO>http://www.isrctn.com/ISRCTN22063938</SO>
<YR>(accessed 6 December 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779926"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2018-02-19 13:49:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779925"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Kim 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim HI, Hyung WJ, Song KJ, Choi SH, Kim CB, Noh SH</AU>
<TI>Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2011</YR>
<VL>18</VL>
<PG>3711-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775088"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775087"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolber-2014" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Kolber 2014" YEAR="2014">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolber MR, Houle SK</AU>
<TI>Oral vitamin B12: a cost-effective alternative</TI>
<SO>Canadian Family Physician</SO>
<YR>2014</YR>
<VL>60</VL>
<PG>111-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775090"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775089"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kripke-2006" MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" NAME="Kripke 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kripke C</AU>
<TI>Is oral vitamin B12 as effective as intramuscular injection?</TI>
<SO>American Family Physician</SO>
<YR>2006</YR>
<VL>73</VL>
<PG>65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775092"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775091"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leidenmuhler-2013" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Leidenmuhler 2013" YEAR="2013">
<REFERENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shakeri-Leidenmuhler S, Poglitsch M, Kefurt R, Felberbauer FX, Bohdjalian A, Langer FB, et al</AU>
<TI>Vitamin B12 substitution after gastric bypass surgery: sublingual or intramuscular?</TI>
<SO>European Surgery - Acta Chirurgica Austriaca</SO>
<YR>2013</YR>
<VL>45</VL>
<NO>2 Suppl</NO>
<PG>S4 (O33)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779928"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779927"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leon-2013" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Leon 2013" YEAR="2013">
<REFERENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leon CA, Georges P, Zaeeter W</AU>
<TI>Vitamin B12 deficiency</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<PG>2041</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775094"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775093"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2012" MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" NAME="Lin 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin J, Kelsberg G, Safranek S</AU>
<TI>Clinical inquiry: Is high-dose oral B12 a safe and effective alternative to a B12 injection?</TI>
<SO>Journal of Family Practice</SO>
<YR>2012</YR>
<VL>61</VL>
<PG>162-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775096"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775095"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lonn-2006" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Lonn 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lonn E</AU>
<TI>Dr. Lonn replies</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>209-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775098"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775097"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masucci-2013" MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" NAME="Masucci 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-09 12:53:09 +0200" MODIFIED_BY="Bernd Richter" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masucci L, Goeree R</AU>
<TI>Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis</TI>
<SO>Ontario Health Technology Assessment Series</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>1-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775100"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775099"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metaxas-2013" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Metaxas 2013" YEAR="2013">
<REFERENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metaxas C, Schmutz A, Walter P, Hersberger KE</AU>
<TI>Oral versus parenteral route of application: the patient's preference</TI>
<SO>International Journal of Clinical Pharmacy</SO>
<YR>2013</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1295-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775102"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775101"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metaxas-2017" MODIFIED="2017-10-25 12:44:29 +0200" MODIFIED_BY="[Empty name]" NAME="Metaxas 2017" YEAR="2017">
<REFERENCE MODIFIED="2017-10-25 12:44:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Metaxas C, Mathis D, Jeger C, Hersberger KE, Arnet I, Walter P</AU>
<TI>Early biomarker response and patient preferences to oral and intramuscular vitamin B12 substitution in primary care: a randomised parallel-group trial</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2017</YR>
<VL>147</VL>
<PG>w14421</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779930"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779929"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-NCT00699478" MODIFIED="2018-02-19 13:40:14 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00699478" YEAR="">
<REFERENCE MODIFIED="2018-02-19 13:39:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Oral vitamin B12 administration for vitamin B12 deficiency after total gastrectomy</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00699478</SO>
<YR>(accessed 6 December 2017)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779932"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2018-02-19 13:40:10 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779931"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pacholok-2013" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Pacholok 2013" YEAR="2013">
<REFERENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pacholok SM</AU>
<TI>Vitamin B12 deficiency: serious consequences</TI>
<SO>Pharmacy Times</SO>
<YR>2013</YR>
<VL>80</VL>
<NO>2</NO>
<PG>1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4242068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775109"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radziwill-2014" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Radziwill 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radziwill R</AU>
<TI>Can a vitamin B12 deficiency in PPI intake be offset by an increased intake of oral B12?</TI>
<SO>Medizinische Monatsschrift fur Pharmazeuten</SO>
<YR>2014</YR>
<VL>37</VL>
<PG>299</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2775112"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2775111"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schijns-2016" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Schijns 2016" YEAR="Ovid">
<REFERENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Schijns W, Meer van der L, Deden L, Janssen IMC, Berends FJ, Aarts EO</AU>
<TI>Efficacy of oral versus intramuscular vitamin B12 supplementation following Roux-en-Y gastric bypass</TI>
<SO>Obesity Facts</SO>
<YR>2016</YR>
<VL>9</VL>
<NO>Suppl 1</NO>
<PG>PO3.104</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779933"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schloss-2015" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Schloss 2015" YEAR="2015">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schloss J M, Colosimo M, Airey C, Vitetta L</AU>
<TI>Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2015</YR>
<VL>23</VL>
<PG>1843-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779936"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779935"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stabler-2015" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Stabler 2015" YEAR="2015">
<REFERENCE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stabler SP</AU>
<TI>Anemias due to essential nutrient deficiencies</TI>
<SO>World Review of Nutrition &amp; Dietetics</SO>
<YR>2015</YR>
<VL>111</VL>
<PG>164-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779938"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779937"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ashok-2011" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Ashok 2011" YEAR="">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Chacko A</AU>
<TI>Is vitamin B12 tablets as effective as vitamin B12 injections for the treatment of vitamin B12 deficiency?</TI>
<SO>Christian Medical College, Vellore India</SO>
<YR>2011</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779940"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779939"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-EUCTR-2009_x002d_014468_x002d_20_x002d_AT" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="EUCTR 2009-014468-20-AT" YEAR="">
<REFERENCE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>A prospective comparison of vitamin B12 supplementation after gastric bypass surgery (sublingual vs. intramuscular)</TI>
<SO>https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014468-20/AT</SO>
<YR>(accessed 6 December 2017)</YR>
<IDENTIFIERS MODIFIED="2016-08-24 18:00:21 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-08-24 18:00:21 +0200" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779942"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2018-02-07 20:15:57 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779941"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01476007" MODIFIED="2018-02-07 20:17:44 +0100" MODIFIED_BY="[Empty name]" NAME="NCT01476007" YEAR="2015">
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Área de Investigación</AU>
<TI>Oral versus intramuscular cobalamin to treat cobalamin deficiency: noninferiority randomised controlled trial, pragmatic and multi-center in the primary healthcare setting (OB12 project)</TI>
<SO>Consorcio de Apoyo a la Investigación Biomédica en red (CAIBER)</SO>
<YR>2011</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779944"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gerencia de Atención Primaria Madrid</AU>
<TI>Oral/intramuscular B12 to treat cobalamin deficiency</TI>
<SO>Instituto de Salud Carlos III</SO>
<YR>2015</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779945"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanz-Cuesta T, González-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-González I, Martín-Fernández J, et al</AU>
<TI>Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multi-centre, non-inferiority clinical trial undertaken in the primary healthcare setting (Project OB12)</TI>
<SO>BMC Public Health</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>394</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7779946"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2018-02-07 20:17:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7779943"/><IDENTIFIER MODIFIED="2018-02-07 20:17:44 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01476007"/><IDENTIFIER MODIFIED="2018-02-07 20:15:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="EudraCT number 2010-024129-20"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2018-02-26 13:21:16 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2018-02-26 13:21:16 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Allen-2009" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Allen L</AU>
<TI>How common is vitamin B-12 deficiency?</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2009</YR>
<VL>89</VL>
<PG>693-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andres-2004" MODIFIED="2016-01-20 12:33:17 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Andres 2004" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Loukili NH, Noel E, Kaltenbach G, Ben Abdelgheni M, Perrin AE, et al</AU>
<TI>Vitamin B12 (cobalamin) deficiency in elderly patients</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>3</NO>
<PG>251-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andres-2008" MODIFIED="2016-08-25 04:39:01 +0200" MODIFIED_BY="[Empty name]" NAME="Andres 2008" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Vogel T, Federici L, Zimmer J, Kaltenbach G</AU>
<TI>Update on oral cyanocobalamin (vitamin B12) treatment in elderly patients</TI>
<SO>Drugs and Aging</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>11</NO>
<PG>927-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andres-2009" MODIFIED="2016-08-24 14:51:01 +0200" MODIFIED_BY="[Empty name]" NAME="Andres 2009" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Serraj K, Mecili M, Ciobanu E, Vogel T, Weitten T</AU>
<TI>Update of oral vitamin B12</TI>
<SO>Annales d Endocrinologie</SO>
<YR>2009</YR>
<VL>70</VL>
<NO>6</NO>
<PG>455-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andres-2010" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Andres 2010" TYPE="JOURNAL_ARTICLE">
<AU>Andres E, Fothergill H, Mecili M</AU>
<TI>Efficacy of oral cobalamin (vitamin B12) therapy</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>2</NO>
<PG>249-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1991" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Anonymous 1991" TYPE="OTHER">
<TI>Dietary reference values for food energy and nutrients for the United Kingdom. Report of the panel on dietary reference values of the committee on medical aspects of food policy</TI>
<SO>Report on Health and Social Subjects</SO>
<YR>1991</YR>
<VL>41</VL>
<PG>1-210</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bahadir-2015" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Bahadir 2015" TYPE="JOURNAL_ARTICLE">
<AU>Bahadir A, Reis PG, Erduran E</AU>
<TI>Oral vitamin B12 treatment is effective for children with nutritional vitamin B12 deficiency</TI>
<SO>Journal of Paediatrics and Child Health</SO>
<YR>2014</YR>
<VL>50</VL>
<NO>9</NO>
<PG>721-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1968" NAME="Berlin 1968" TYPE="JOURNAL_ARTICLE">
<AU>Berlin H, Berlin R, Brante G</AU>
<TI>Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1968</YR>
<VL>184</VL>
<NO>4</NO>
<PG>247-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1978" NAME="Berlin 1978" TYPE="JOURNAL_ARTICLE">
<AU>Berlin R, Berlin H, Brante G, Pilbrant A</AU>
<TI>Vitamin B12 body stores during oral and parenteral treatment of pernicious anaemia</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1978</YR>
<VL>204</VL>
<NO>1-2</NO>
<PG>81-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2004" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="BNF 2004" TYPE="BOOK">
<AU>British Medical Association, Royal Pharmaceutical Society of Great Britain</AU>
<SO>British National Formulary</SO>
<YR>2004</YR>
<VL>48</VL>
<PG>456-7</PG>
<EN>63rd revised</EN>
<PB>British Medical Association</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boddy-1968" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Boddy 1968" TYPE="JOURNAL_ARTICLE">
<AU>Boddy K, King P, Mervyn L, Macleod A, Adams JF</AU>
<TI>Retention of cyanocobalamin, hydroxocobalamin, and coenzyme B 12 after parenteral administration</TI>
<SO>Lancet</SO>
<YR>1968</YR>
<VL>292</VL>
<NO>7570</NO>
<PG>710-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boutron-2014" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Boutron 2014" TYPE="JOURNAL_ARTICLE">
<AU>Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P</AU>
<TI>Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2014</YR>
<VL>32</VL>
<PG>4120-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brito-2015" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Brito 2015" TYPE="JOURNAL_ARTICLE">
<AU>Brito A, Mujica-Coopman MF, López de Romaña D, Cori H, Allen LH</AU>
<TI>Folate and vitamin B12 status in Latin America and the Caribbean: an update</TI>
<SO>Food and Nutrition Bulletin</SO>
<YR>2015</YR>
<VL>36</VL>
<NO>Suppl 2</NO>
<PG>S109-18</PG>
<IDENTIFIERS MODIFIED="2016-08-24 16:25:36 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-08-24 16:25:36 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1177/0379572115585772"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Castelli-2011" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Castelli 2011" TYPE="JOURNAL_ARTICLE">
<AU>Castelli MC, Friedman K, Sherry J, Brazzillo K, Genoble L, Bhargava P, et al</AU>
<TI>Comparing the efficacy and tolerability of a new daily oral vitamin B12 formulation and intermittent intramuscular vitamin B12 in normalizing low cobalamin levels: a randomized, open-label, parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>3</NO>
<PG>358-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2004" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2004" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, et al</AU>
<TI>Vitamin B12 and folate deficiency in later life</TI>
<SO>Age and Ageing</SO>
<YR>2004</YR>
<VL>33</VL>
<PG>34-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Jager-2010" MODIFIED="2016-08-25 04:52:11 +0200" MODIFIED_BY="[Empty name]" NAME="De Jager 2010" TYPE="JOURNAL_ARTICLE">
<AU>De Jager J, Kooy A, Lehert P, Wulffelé MG, Van der Kolk J, Bets D, et al</AU>
<TI>Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c2181</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elia-1998" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Elia 1998" TYPE="JOURNAL_ARTICLE">
<AU>Elia M</AU>
<TI>Oral or parenteral therapy for B12 deficiency</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9142</NO>
<PG>1721-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FAO_x002f_WHO-1988" MODIFIED="2018-02-19 13:58:18 +0100" MODIFIED_BY="[Empty name]" NAME="FAO/WHO 1988" TYPE="BOOK">
<AU>Report of a Joint FAO/WHO Expert Consultation</AU>
<TI>Requirements of vitamin A, iron, folate and vitamin B12. Report of a Joint FAO/WHO Expert Consultation</TI>
<SO>FAO Food and Nutrition Series</SO>
<YR>1988</YR>
<VL>23</VL>
<PB>Food and Agriculture Organization of the United Nations; World Health Organization</PB>
<CY>Rome</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Figlin-2003" MODIFIED="2008-11-05 22:16:16 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Figlin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Figlin E, Chetrit A, Shahar A, Shpilberg O, Zivelin A, Rosenberg N, et al</AU>
<TI>High prevalences of vitamin B12 and folic acid deficiency in elderly subjects in Israel</TI>
<SO>British Journal of Haematology</SO>
<YR>2003</YR>
<VL>123</VL>
<PG>696-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glass-1961" MODIFIED="2016-01-20 12:46:45 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Glass 1961" TYPE="JOURNAL_ARTICLE">
<AU>Glass GB, Skeggs HR, Lee DH, Jones EL, Hardy WW</AU>
<TI>Hydroxocobalamin. I. Blood levels and urinary excretion of vitamin B12 in man after a single parenteral dose of aqueous hydroxocobalamin, aqueous cyanocobalamin and cyanocobalamin zinc-tannate complex</TI>
<SO>Blood</SO>
<YR>1961</YR>
<VL>18</VL>
<PG>511-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2007" MODIFIED="2017-07-05 12:19:00 +0200" MODIFIED_BY="[Empty name]" NAME="Graham 2007" TYPE="JOURNAL_ARTICLE">
<AU>Graham ID, Jette N, Tetroe J, Robinson N, Milne S, Mitchell SL</AU>
<TI>Oral cobalamin remains medicine's best kept secret</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>2007</YR>
<VL>44</VL>
<NO>1</NO>
<PG>49-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2013" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Green 2013" TYPE="JOURNAL_ARTICLE">
<AU>Green</AU>
<TI>Physiology, dietary sources, and requirements</TI>
<SO>Encyclopedia of Human Nutrition</SO>
<YR>2013</YR>
<VL>4</VL>
<PG>351-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-1977" MODIFIED="2017-07-05 12:20:28 +0200" MODIFIED_BY="[Empty name]" NAME="Hall 1977" TYPE="JOURNAL_ARTICLE">
<AU>Hall CA</AU>
<TI>The carriers of native vitamin B12 in normal human serum</TI>
<SO>Clinical Science and Molecular Medicine</SO>
<YR>1977</YR>
<VL>53</VL>
<PG>453-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-05-15 15:20:51 +0200" MODIFIED_BY="G P" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2013-05-15 15:20:51 +0200" MODIFIED_BY="G P" NAME="Higgins 2009" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Spiegelhalter DJ</AU>
<TI>A re-evaluation of random-effects meta-analysis</TI>
<SO>Journal of the Royal Statistical Society: Series A (Statistics in Society)</SO>
<YR>2009</YR>
<VL>172</VL>
<NO>1</NO>
<PG>137-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2018-02-08 03:45:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d5928</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hozo-2005" MODIFIED="2016-01-20 13:14:21 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Hozo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hozo SP, Djulbegovic B, Hozo I</AU>
<TI>Estimating the mean and variance from the median, range, and the size of a sample</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>13</PG>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1186/1471-2288-5-13"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hr_x00f3_bjartsson-2013" MODIFIED="2015-06-10 16:41:28 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hróbjartsson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al</AU>
<TI>Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2013</YR>
<VL>185</VL>
<NO>4</NO>
<PG>E201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al</AU>
<TI>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1136/bmj.c365"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lam-2013" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Lam 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lam JR, Schneider JL, Zhao W, Corley DA</AU>
<TI>Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency</TI>
<SO>JAMA</SO>
<YR>2013</YR>
<VL>310</VL>
<PG>2435-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lederle-1998" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Lederle 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lederle FA</AU>
<TI>Oral cobalamin for pernicious anemia: back from the verge of extinction</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1998</YR>
<VL>46</VL>
<PG>1125-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2015-06-10 16:42:35 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al</AU>
<TI>The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>1-28</PG>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1371/journal.pmed.1000100"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lindenbaum-1994" MODIFIED="2008-11-05 22:15:56 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Lindenbaum 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH</AU>
<TI>Prevalence of cobalamin deficiency in the Framingham elderly population</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<NO>1</NO>
<PG>2-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacFarlane-2011" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="MacFarlane 2011" TYPE="JOURNAL_ARTICLE">
<AU>MacFarlane AJ, Greene-Finestone LS, Shi Y</AU>
<TI>Vitamin B-12 and homocysteine status in a folate-replete population</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2011</YR>
<VL>94</VL>
<NO>4</NO>
<PG>1079-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathieu-2009" MODIFIED="2015-06-15 14:19:12 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Mathieu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P</AU>
<TI>Comparison of registered and published primary outcomes in randomized controlled trials</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<PG>977-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meader-2014" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Meader 2014" TYPE="JOURNAL_ARTICLE">
<AU>Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al</AU>
<TI>A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation</TI>
<SO>Systematic Reviews</SO>
<YR>2014</YR>
<VL>3</VL>
<PG>82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Middleton-1985" MODIFIED="2017-07-05 12:23:55 +0200" MODIFIED_BY="[Empty name]" NAME="Middleton 1985" TYPE="JOURNAL_ARTICLE">
<AU>Middleton J, Wells W</AU>
<TI>Vitamin B12 injections: considerable source of work for the district nurse</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>290</VL>
<NO>6477</NO>
<PG>1254-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nilsson-2005" NAME="Nilsson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson M, Norberg B, Hultdin J, Sandstrom H, Westman G, Lokk J</AU>
<TI>Medical intelligence in Sweden. Vitamin B12: oral compared with parenteral?</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2005</YR>
<VL>81</VL>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pawlak-2013" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Pawlak 2013" TYPE="JOURNAL_ARTICLE">
<AU>Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D</AU>
<TI>How prevalent is vitamin B12 deficiency among vegetarians?</TI>
<SO>Nutrition Reviews</SO>
<YR>2013</YR>
<VL>71</VL>
<NO>2</NO>
<PG>110-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pawlak-2015" MODIFIED="2018-02-08 06:26:53 +0100" MODIFIED_BY="[Empty name]" NAME="Pawlak 2015" TYPE="JOURNAL_ARTICLE">
<AU>Pawlak R</AU>
<TI>Is vitamin B12 deficiency a risk factor for cardiovascular disease in vegetarians?</TI>
<SO>American Journal of Preventive Medicine</SO>
<YR>2015</YR>
<VL>48</VL>
<NO>6</NO>
<PG>e11-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pennypacker-1992" MODIFIED="2008-11-05 22:15:38 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Pennypacker 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K</AU>
<TI>High prevalence of cobalamin deficiency in elderly outpatients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1992</YR>
<VL>40</VL>
<PG>1197-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quadros--2010" MODIFIED="2017-07-05 12:27:58 +0200" MODIFIED_BY="[Empty name]" NAME="Quadros  2010" TYPE="JOURNAL_ARTICLE">
<AU>Quadros E</AU>
<TI>Advances in the understanding of cobalamin assimilation and metabolism</TI>
<SO>British Journal of Haematology</SO>
<YR>2010</YR>
<VL>148</VL>
<PG>195-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajan-2002" MODIFIED="2008-11-05 22:15:34 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Rajan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Rajan S, Wallace JI, Beresford SA, Brodkin KI, Allen RA, Stabler SP</AU>
<TI>Screening for cobalamin deficiency in geriatric outpatients: prevalence and influence of synthetic cobalamin intake</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>4</NO>
<PG>624-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-06-13 10:26:14 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rickes-1948" NAME="Rickes 1948" TYPE="JOURNAL_ARTICLE">
<AU>Rickes EL, Brink NG, Koniuszy FR, Wood TR, Folkers K</AU>
<TI>Crystalline vitamin B12</TI>
<SO>Science</SO>
<YR>1948</YR>
<VL>107</VL>
<PG>396</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2011" MODIFIED="2013-05-15 15:20:51 +0200" MODIFIED_BY="G P" NAME="Riley 2011" TYPE="JOURNAL_ARTICLE">
<AU>Riley RD, Higgins JP, Deeks JJ</AU>
<TI>Interpretation of random effects meta-analyses</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d549</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schroll-2015" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NAME="Schroll 2015" TYPE="OTHER">
<AU>Schroll JB, Bero L</AU>
<TI>Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<VL>4</VL>
<IDENTIFIERS MODIFIED="2018-02-08 04:03:23 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2018-02-08 04:03:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.ED000098"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1948" NAME="Smith 1948" TYPE="JOURNAL_ARTICLE">
<AU>Smith EL</AU>
<TI>Purification of anti-pernicious anaemia factor from liver</TI>
<SO>Nature</SO>
<YR>1948</YR>
<VL>161</VL>
<PG>638</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stabler-2013" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Stabler 2013" TYPE="JOURNAL_ARTICLE">
<AU>Stabler SP</AU>
<TI>Clinical practice. Vitamin B12 deficiency</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>2</NO>
<PG>149-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Walraven-1999" NAME="van Walraven 1999" TYPE="JOURNAL_ARTICLE">
<AU>van Walraven C, Naylor CD</AU>
<TI>Use of vitamin B12 injections among elderly patients by primary care practitioners in Ontario</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1999</YR>
<VL>161</VL>
<PG>146-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-2013" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Watanabe 2013" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe F, Yabuta Y, Tanioka Y</AU>
<TI>Biologically active vitamin B12 compounds in foods for preventing deficiency among vegetarians and elderly</TI>
<SO>Journal of Agricultural and Food Chemistry</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>28</NO>
<PG>6769-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2006" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Wong 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wong SSL, Wilczynski NL, Haynes RB</AU>
<TI>Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Vidal_x002d_Alaball-2005" MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]" NAME="Vidal-Alaball 2005" TYPE="COCHRANE_REVIEW">
<AU>Vidal-Alaball J, Butler CC, Cannings-John R, Goringe A, Hood K, McCaddon A, et al</AU>
<TI>Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004655.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2018-02-19 14:00:08 +0100" MODIFIED_BY="[Empty name]"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2018-02-19 14:00:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim for study"><INCLUDED_CHAR MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bolaman-2003"><CHAR_METHODS MODIFIED="2017-10-25 11:55:46 +0200" MODIFIED_BY="[Empty name]"><P>Parallel randomised controlled clinical trial; randomisation ratio 1:1; open label; observation period 90 days</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Inclusion criteria: </B>people with megaloblastic anaemia due to vitamin B<SUB>12</SUB> deficiency</P><UL><LI>Age &gt; 15 years</LI><LI>Serum vitamin B<SUB>12</SUB> level &lt; 160 pg/mL</LI><LI>Megaloblastic anaemia</LI><LI>MCV &gt; 94 fL</LI></UL><P><B>Exclusion criteria:</B></P><UL><LI>vomiting or diarrhoea or both, alcohol use &gt; 40 g/d</LI><LI>unable to give informed consent</LI><LI>history of malignancy</LI><LI>folate deficiency</LI><LI>inability to ingest oral medication</LI><LI>use of medication that might interfere with folate metabolism</LI><LI>pregnant or possibly pregnant</LI><LI>breastfeeding</LI></UL><P><B>Diagnostic criteria:</B> people with megaloblastic anaemia due to vitamin B<SUB>12</SUB> deficiency</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-25 11:57:08 +0200" MODIFIED_BY="[Empty name]"><P><B>Number of study centres: </B>1</P><P><B>Treatment before study:</B> unknown<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-06-01 16:47:00 +0200" MODIFIED_BY="[Empty name]"><P><B>Composite outcome measures reported:</B> no</P></CHAR_OUTCOMES><CHAR_USER_DEF_1 MODIFIED="2017-10-25 11:57:20 +0200" MODIFIED_BY="[Empty name]"><P><B>Run-in period:</B> none</P><P><B>Study terminated early:</B> no</P></CHAR_USER_DEF_1><CHAR_USER_DEF_2 MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Language of publication:</B> English</P><P><B>Commercial funding/non-commercial funding/other funding: </B>unknown</P><P><B>Publication status: </B>peer-reviewed journal</P></CHAR_USER_DEF_2><CHAR_USER_DEF_3 MODIFIED="2018-02-07 18:28:59 +0100" MODIFIED_BY="[Empty name]"><P><B>Quote from publication:</B> "This study assessed the effects and cost of PO versus IM vitamin B<SUB>12</SUB> treatment in patients with megaloblastic anaemia duo to vitamin B<SUB>12</SUB>"</P></CHAR_USER_DEF_3><CHAR_NOTES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-02-19 14:00:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuzminski-1998"><CHAR_METHODS MODIFIED="2017-10-25 11:59:53 +0200" MODIFIED_BY="[Empty name]"><P>Parallel randomised controlled clinical trial; randomisation ratio 1:1; observation period 4 months</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Inclusion criteria:</B></P><UL><LI>Newly diagnosed vitamin B<SUB>12</SUB>-deficient participants</LI><LI>Serum vitamin B<SUB>12</SUB> level &lt; 160 pg/mL</LI><LI>Elevation of serum methylmalonic acid, total homocysteine or both metabolites &gt; 3 SDs above the mean in normal controls</LI></UL><P><B>Exclusion criteria:</B><BR/></P><UL><LI>Location outside immediate geographical area</LI><LI>Incapacity to give informed consent</LI><LI>Associated life-threatening illness</LI><LI>Primary folate deficiency</LI></UL><P><B>Diagnostic criteria:</B> people with newly diagnosed vitamin B<SUB>12</SUB> deficiency (defined as serum vitamin B<SUB>12</SUB> concentrations less than 160 pg/mL)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2017-10-25 12:00:39 +0200" MODIFIED_BY="[Empty name]"><P><B>Number of study centres: </B>4 centres</P><P><B>Treatment before study:</B> unknown<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-10-25 12:00:55 +0200" MODIFIED_BY="[Empty name]"><P><B>Composite outcome measures reported:</B> no</P></CHAR_OUTCOMES><CHAR_USER_DEF_1 MODIFIED="2017-10-25 12:01:04 +0200" MODIFIED_BY="[Empty name]"><P><B>Run-in period:</B> none</P><P><B>Study terminated early:</B> no</P></CHAR_USER_DEF_1><CHAR_USER_DEF_2 MODIFIED="2018-02-19 14:00:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Language of publication:</B> English</P><P><B>Commercial funding/non-commercial funding/other funding:</B> unknown</P><P><B>Publication status: </B>peer-reviewed journal<BR/></P></CHAR_USER_DEF_2><CHAR_USER_DEF_3 MODIFIED="2017-01-10 09:58:32 +0100" MODIFIED_BY="[Empty name]"><P><B>Quote from publication:</B> "However, oral treatment with the vitamin has never been the subject of a controlled study. Therefore, we conducted a randomised, controlled trial of oral versus parenteral cyanocobalamin therapy in patients with vitamin B<SUB>12</SUB> deficiency"<BR/></P></CHAR_USER_DEF_3><CHAR_NOTES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-02-19 14:00:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saraswathy-2012"><CHAR_METHODS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Parallel randomised controlled clinical trial; randomisation ratio 1:1; non-inferiority design; observation period 3 months</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-02-19 14:00:08 +0100" MODIFIED_BY="[Empty name]"><P><B>Inclusion criteria:</B></P><UL><LI>diagnosed vitamin B<SUB>12</SUB>-deficient participants</LI><LI>Serum vitamin B<SUB>12</SUB> level &lt; 200 pg/mL</LI></UL><P><B>Exclusion criteria: </B></P><UL><LI>people aged &lt; 18 years</LI><LI>pregnant individuals</LI><LI>those with special conditions mandating parenteral supplementation</LI><LI>those already on vitamin B<SUB>12</SUB> supplements</LI></UL><P><B>Diagnostic criteria:</B> people with newly diagnosed vitamin B<SUB>12</SUB> deficiency (defined as serum vitamin B<SUB>12</SUB> concentrations less than 200 pg/mL)</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-02-13 13:09:30 +0100" MODIFIED_BY="[Empty name]"><P><B>Number of study centres: </B>1</P><P><B>Treatment before study:</B> unknown</P><P><B>Titration period: </B>not applicable<BR/></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-25 11:36:27 +0100" MODIFIED_BY="[Empty name]"><P><B>Composite outcome measures reported:</B> no</P></CHAR_OUTCOMES><CHAR_USER_DEF_1 MODIFIED="2016-12-23 08:55:00 +0100" MODIFIED_BY="[Empty name]"><P><B>Run-in period:</B> none</P><P><B>Study terminated before regular end:</B> no</P></CHAR_USER_DEF_1><CHAR_USER_DEF_2 MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P><B>Language of publication:</B> English</P><P><B>Commercial funding/non-commercial funding/other funding:</B> unknown</P><P><B>Publication status: </B>peer-reviewed journal; conference abstract providing sufficient information<BR/></P></CHAR_USER_DEF_2><CHAR_USER_DEF_3 MODIFIED="2018-02-07 18:42:44 +0100" MODIFIED_BY="[Empty name]"><P><B>Quote from publication:</B> "To compare the efficacy of oral versus intramuscular vitamin B<SUB>12</SUB> supplementation for the treatment of vitamin B<SUB>12</SUB> deficiency"<BR/></P></CHAR_USER_DEF_3><CHAR_NOTES MODIFIED="2016-12-23 08:54:51 +0100" MODIFIED_BY="[Empty name]"/></INCLUDED_CHAR><FOOTNOTES><P>Note: blank cells indicate that the particular outcome was not measured in trial.<BR/>IM: intramuscular; MCV: mean corpuscular volume; PO: peroral; SD: standard deviation</P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2016-06-01 16:50:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aguilar-2004"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:50:52 +0200" MODIFIED_BY="[Empty name]"><P>Commentary</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:50:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andres-2005a"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:50:55 +0200" MODIFIED_BY="[Empty name]"><P>Review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:50:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andres-2005b"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:50:58 +0200" MODIFIED_BY="[Empty name]"><P>Letter</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andres-2011"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:03 +0200" MODIFIED_BY="[Empty name]"><P>Letter</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Andres-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:06 +0200" MODIFIED_BY="[Empty name]"><P>Review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-12-23 10:02:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bharath-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-23 10:02:10 +0100" MODIFIED_BY="[Empty name]"><P>Case report</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bharatwaj-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:09 +0200" MODIFIED_BY="[Empty name]"><P>Review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Butler-2006"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:12 +0200" MODIFIED_BY="[Empty name]"><P>Systematic review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castelli-2010"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Participants without vitamin B<SUB>12</SUB> deficiency but low vitamin B<SUB>12</SUB> levels only (overall mean: 273 pg/mL (SD 55.2), i.e. borderline result)</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emans-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:14 +0200" MODIFIED_BY="[Empty name]"><P>Letter</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-11-07 15:12:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR-2013_x002d_004835_x002d_60"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-07 15:12:30 +0100" MODIFIED_BY="[Empty name]"><P>Non-randomised trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-11-07 15:12:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geisel-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-07 15:12:27 +0100" MODIFIED_BY="[Empty name]"><P>Non-randomised trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-12-23 10:02:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haffner-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-23 10:02:28 +0100" MODIFIED_BY="[Empty name]"><P>Review of the evidence</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:18 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Houle-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:18 +0200" MODIFIED_BY="[Empty name]"><P>Cost analysis</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-07-02 17:19:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN22063938"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-02 17:19:34 +0200" MODIFIED_BY="[Empty name]"><P>Oral vitamin B<SUB>12</SUB> versus placebo</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-11-07 15:12:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-07 15:12:33 +0100" MODIFIED_BY="[Empty name]"><P>Non-randomised single-arm trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-11-07 15:12:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolber-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-07 15:12:36 +0100" MODIFIED_BY="[Empty name]"><P>Non-randomised trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-11-07 15:12:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kripke-2006"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-11-07 15:12:39 +0100" MODIFIED_BY="[Empty name]"><P>Non-randomised trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-12-24 12:42:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leidenmuhler-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-24 12:42:39 +0100" MODIFIED_BY="[Empty name]"><P>All participants received a multivitamin mineral supplementation on a daily basis. </P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leon-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:21 +0200" MODIFIED_BY="[Empty name]"><P>Commentary</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:24 +0200" MODIFIED_BY="[Empty name]"><P>Commentary</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lonn-2006"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:27 +0200" MODIFIED_BY="[Empty name]"><P>Letter</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Masucci-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:29 +0200" MODIFIED_BY="[Empty name]"><P>Review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-06-01 16:51:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Metaxas-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-01 16:51:33 +0200" MODIFIED_BY="[Empty name]"><P>Review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Metaxas-2017"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Eligible participants had a vitamin B<SUB>12</SUB> level &lt; 200 pmol/L (i.e. borderline result), mean vitamin B<SUB>12</SUB> levels at inclusion were 158 pmol/L ± 27 pmol/L and 164 pmol/L ± 20 pmol/L for the oral and intramuscular group, respectively.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00699478"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Non-randomised single-arm trial</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-05-04 15:20:04 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Pacholok-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-04 15:20:04 +0200" MODIFIED_BY="Bernd Richter"><P>Commentary</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-05-04 15:16:15 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Radziwill-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-04 15:16:15 +0200" MODIFIED_BY="Bernd Richter"><P>Commentary</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schijns-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><P>Mean vitamin B<SUB>12</SUB> levels at inclusion were 170 pmol/L ± 22 pmol/L (i.e. borderline result), also conference abstract only.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-12-26 12:58:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schloss-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-26 12:58:37 +0100" MODIFIED_BY="[Empty name]"><P>Case report</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2016-12-23 10:07:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stabler-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-23 10:07:16 +0100" MODIFIED_BY="[Empty name]"><P>Review</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES><P>SD: standard deviation</P></FOOTNOTES></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><AWAITING_CHAR MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ashok-2011"><CHAR_METHODS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Randomised, parallel-group trial; total sample size N = 38</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Diagnosis: </B>all participants with documented vitamin B<SUB>12</SUB> deficiency (serum vitamin B<SUB>12</SUB> level &lt; 200 pg/mL)</P><P><B>Age:</B> 18 to 80 years old</P><P><B>Exclusion criteria:</B></P><UL><LI>age less than 18 years</LI><LI>pregnant individuals</LI><LI>renal failure</LI><LI>special cases where parenteral B<SUB>12</SUB> supplementation is mandatory (e.g. people with severe neurological deficits, intestinal failure, etc.)</LI><LI>already taking vitamin B<SUB>12</SUB> supplements</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Group 1:</B> oral vitamin B<SUB>12</SUB> 1000 mcg once daily for 3 months</P><P><B>Group 2:</B> intramuscular injections of vitamin B<SUB>12</SUB> once daily for a week, followed by once a week for 8 weeks, followed by once-a-month injection for 1 month (total duration 3 months)</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Primary outcome:</B> serum vitamin B<SUB>12</SUB> levels (3 months after initiation of therapy)</P><P><B>Secondary outcomes:</B> change in haemoglobin, mean corpuscular volume, serum homocysteine, clinical symptoms (3 months)</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Awaiting full text</P><P><B>Contact information: </B></P><P>Arun RS, assistant professor, Christian Medical College, Vellore; drarunrs@gmail.com Ashok Chacko, professor and head, Christian Medical College, Vellore; chacko.ashok@gmail.com</P><P>Trial was registered retrospectively; trial is completed.</P></CHAR_NOTES></AWAITING_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study identifier" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Official title" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated purpose of study"><ONGOING_CHAR MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR-2009_x002d_014468_x002d_20_x002d_AT"><CHAR_STUDY_NAME MODIFIED="2018-02-07 18:58:34 +0100" MODIFIED_BY="[Empty name]"><P><B>Acronym:</B> not stated</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2016-03-25 13:30:17 +0100" MODIFIED_BY="[Empty name]"><P><B>Type of study:</B> not stated</P><P><B>Allocation: </B>not stated</P><P><B>Intervention model:</B> not stated</P><P><B>Masking: </B>not stated</P><P><B>Primary purpose:</B> not stated</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Condition:</B> vitamin B<SUB>12</SUB> deficiency undergoing gastric bypass surgery</P><P><B>Enrolment:</B> not stated</P><P><B>Inclusion criteria:</B> not stated</P><P><B>Exclusion criteria:</B> not stated</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2016-07-02 17:19:48 +0200" MODIFIED_BY="[Empty name]"><P><B>Intervention(s):</B> sublingual vitamin B<SUB>12</SUB></P><P><B>Comparator(s):</B> intramuscular vitamin B<SUB>12</SUB></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2016-03-25 13:30:41 +0100" MODIFIED_BY="[Empty name]"><P><B>Primary outcome(s):</B> not stated</P><P><B>Secondary outcome(s):</B> not stated</P><P><B>Other outcome(s):</B> not stated</P></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Study start date:</B> 22 March 2010</P><P><B>Study completion date:</B> not stated</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Responsible party/principal investigator: </B>Medizinische Universität Wien, Univ.Klinik für Chirurgie, Abt.für Allgemeinchirurgie</P></CHAR_CONTACT_INFORMATION><CHAR_USER_DEF_1 MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>EudraCT number:</B> EUCTR2009-014468-20-AT</P></CHAR_USER_DEF_1><CHAR_USER_DEF_2 MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>A prospective comparison of vitamin B<SUB>12</SUB> supplementation after gastric bypass surgery (sublingual vs intramuscular)</P></CHAR_USER_DEF_2><CHAR_USER_DEF_3 MODIFIED="2017-01-16 12:34:47 +0100" MODIFIED_BY="[Empty name]"><P>Not stated</P></CHAR_USER_DEF_3><CHAR_NOTES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"/></ONGOING_CHAR><ONGOING_CHAR MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01476007"><CHAR_STUDY_NAME MODIFIED="2016-03-25 13:31:26 +0100" MODIFIED_BY="[Empty name]"><P><B>Acronym:</B> Project OB12</P></CHAR_STUDY_NAME><CHAR_METHODS MODIFIED="2016-03-25 13:31:42 +0100" MODIFIED_BY="[Empty name]"><P><B>Type of study:</B> non-inferiority clinical trial</P><P><B>Allocation: </B>randomisation</P><P><B>Intervention model:</B> parallel assignment</P><P><B>Masking:</B> open label</P><P><B>Primary purpose:</B> treatment</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P><B>Condition:</B> vitamin B<SUB>12 </SUB>deficiency, defined as serum vitamin B<SUB>12</SUB> &lt; 179 pg/mL</P><P><B>Enrolment:</B> estimated 320</P><P><B>Inclusion criteria:</B></P><UL><LI>&#8805; 65 aged patients with vitamin B<SUB>12</SUB> deficiency</LI><LI>participants give informed consent</LI></UL><P><B>Exclusion criteria:</B></P><UL><LI>treatment with B<SUB>12</SUB> (last year)</LI><LI>neurologic or psychiatric pathologies</LI><LI>folic acid &lt; 2.3 ng/mL</LI></UL></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2016-07-02 17:20:16 +0200" MODIFIED_BY="[Empty name]"><P><B>Intervention(s):</B> oral vitamin B<SUB>12</SUB></P><P><B>Comparator(s):</B> intramuscular vitamin B<SUB>12</SUB></P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2017-10-26 12:19:59 +0200" MODIFIED_BY="[Empty name]"><P><B>Primary outcome(s):</B></P><UL><LI>change from baseline in vitamin B<SUB>12</SUB> level at 52 weeks</LI><LI>change from vitamin B<SUB>12</SUB> level standardisation</LI></UL><P><B>Secondary outcome(s):</B> not stated</P><P><B>Other outcome(s):</B> none</P></CHAR_OUTCOMES><CHAR_STARTING_DATE MODIFIED="2017-10-25 18:05:42 +0200" MODIFIED_BY="[Empty name]"><P><B>Study start date:</B> July 2014; ongoing but not recruiting participants</P><P><B>Study completion date:</B> December 2017</P></CHAR_STARTING_DATE><CHAR_CONTACT_INFORMATION MODIFIED="2018-02-07 19:03:59 +0100" MODIFIED_BY="[Empty name]"><P><B>Responsible party/principal investigator</B>:</P><P>Esperanza Escortell, Epidemiology, phone 34 91 3352569, email eescortell@salud.madrid.org</P><P>Rosario Riesgo, Epidemiology, phone 34 91 6956672, email rriesgo@salud.madrid.org</P></CHAR_CONTACT_INFORMATION><CHAR_USER_DEF_1 MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>ClinicalTrials.gov: NCT01476007</P><P>EudraCT number: 2010-024129-20</P></CHAR_USER_DEF_1><CHAR_USER_DEF_2 MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>Oral/intramuscular B<SUB>12</SUB> to treat cobalamin deficiency</P></CHAR_USER_DEF_2><CHAR_USER_DEF_3 MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><P>To determine the effectiveness of oral versus intramuscular vitamin B<SUB>12 </SUB>by restore vitamin B<SUB>12</SUB> parameter in blood at 8, 26, and 52 weeks in &#8805; 65 aged patients with vitamin B<SUB>12</SUB> deficiency</P></CHAR_USER_DEF_3><CHAR_NOTES MODIFIED="2018-02-07 19:06:21 +0100" MODIFIED_BY="[Empty name]"><P><B>NCT number:</B> NCT01476007</P></CHAR_NOTES></ONGOING_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2018-02-07 18:43:23 +0100" MODIFIED_BY="[Empty name]" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-26 15:30:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publication: </B>"using the block randomizations method"</P><P><B>Comment:</B> no details provided</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-01 16:49:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Quote from publication: </B>"... patients were randomized (Statistical Analysis System; SAS Institute, Cary, NC) ..."</P><P><B>Comment:</B> computer randomisation<BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-02-07 18:43:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Quote from publication: </B>"... randomised and allocated in a concealed manner ..."</P><P><B>Comment: </B>the method of randomisation is not reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-01 16:47:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Comment:</B> no details provided</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-01 16:49:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Quote from publication: </B>"... randomised and allocated in a concealed manner ..."</P><P><B>Comment: </B>the allocation was concealed, but no details were provided.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NO="7"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.11" NO="11" REF_IDS="CMP-001.06"><NAME>total homocysteine and serum methylmalonic acid levels</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.03" NO="3" REF_IDS="CMP-001.03"><NAME>adverse events</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.04" NO="4"><NAME>acceptability</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.09" NO="9" REF_IDS="CMP-001.01"><NAME>serum vitamin B12 levels</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.10" NO="10"><NAME>socioeconomic effects</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.08" NO="8"><NAME>health-related quality of life</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.05" NO="5"><NAME>clinical signs and symptoms of vitamin B12 deficiency</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.07" NO="7" REF_IDS="CMP-001.04"><NAME>haemoglobin and mean corpuscular volume (MCV)</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publicatio</B>n<B>:</B> "open-label study"</P><P><B>Comment:</B> outcome measure likely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-12-26 15:27:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2016-12-26 15:28:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publication: </B>"open-label"<BR/><B>Comment:</B> outcome measure unlikely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2016-06-01 16:47:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.09" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publication: </B>"open-label"<BR/><B>Comment:</B> outcome measure unlikely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.10" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publicatio</B>n<B>:</B> "open-label study"</P><P><B>Comment:</B> outcome measure unlikely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.11" MODIFIED="2016-06-01 16:47:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2016-12-26 15:34:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-12-26 15:33:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2016-12-26 15:34:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2016-06-01 16:50:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.09" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.10" MODIFIED="2016-06-01 16:50:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.11" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.03" MODIFIED="2017-10-26 12:40:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Quote from publication: </B>"Randomized open label trial ..."</P><P><B>Comment:</B> not reported, outcome measure likely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.08" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.09" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Quote from publication: </B>"Randomized open label trial ..."</P><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.10" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Quote from publication: </B>"Randomized open label trial ..."</P><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.11" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="8"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.10" NO="10"><NAME>socioeconomic effects</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.04" NO="4"><NAME>acceptability</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.06" NO="6" REF_IDS="CMP-001.04"><NAME>haemoglobin and mean corpuscular volume (MCV)</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.03" NO="3" REF_IDS="CMP-001.03"><NAME>adverse events</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.05" NO="5"><NAME>clinical signs and symptoms of vitamin B12 deficiency</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.11" NO="11" REF_IDS="CMP-001.06"><NAME>total homocysteine and serum methylmalonic acid levels</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.07" NO="7"><NAME>health-related quality of life</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.09" NO="9" REF_IDS="CMP-001.07"><NAME>serum vitamin B12 levels</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publicatio</B>n<B>:</B> "open-label study"</P><P><B>Comment:</B> outcome measure likely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-12-26 15:27:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2016-12-26 15:27:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publicatio</B>n<B>:</B> "open-label study"</P><P><B>Comment:</B> outcome measure unlikely to be influenced by lack of blinding</P><P><BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-06-01 16:47:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publicatio</B>n<B>:</B> "open-label study"</P><P><B>Comment:</B> outcome measure unlikely to be influenced by lack of blinding</P><P><BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publicatio</B>n<B>:</B> "open-label study"</P><P><B>Comment:</B> outcome measure unlikely to be influenced by lack of blinding</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.11" MODIFIED="2016-06-01 16:47:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2016-06-01 16:49:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-06-01 16:49:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2016-12-26 15:42:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-06-01 16:50:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2016-06-01 16:50:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.11" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.03" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.09" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.10" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Comment:</B> not reported, outcome measure unlikely to be affected by blinding conditions</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.11" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4" REF_IDS="CMP-001.04"><NAME>haemoglobin and mean corpuscular volume (MCV)</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.03"><NAME>adverse events</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2"><NAME>acceptability</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.05" NO="5"><NAME>health-related quality of life</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3"><NAME>clinical signs and symptoms of vitamin B12 deficiency</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.07" NO="7"><NAME>socioeconomic effects</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.06" NO="6" REF_IDS="CMP-001.07"><NAME>serum vitamin B12 levels</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.09" NO="9" REF_IDS="CMP-001.06"><NAME>total homocysteine and serum methylmalonic acid levels</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-01-16 13:27:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Quote from publication: "</B>No treatment-related adverse events were reported in either treatment group"</P><P><B>Comment:</B> no adverse events were reported</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-12-26 15:26:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-12-26 15:27:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-12-26 15:26:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Comment:</B> 10 of 70 participants left the study because they did not appear for follow-up after 10 days of treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2016-06-01 16:47:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-12-26 15:26:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Comment:</B> 10 of 70 participants left the study because they did not appear for follow-up after 10 days of treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-06-01 16:47:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Comment:</B> 10 of 70 participants left the study because they did not appear for follow-up after 10 days of treatment</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.09" MODIFIED="2016-06-01 16:47:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-01 16:49:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2016-06-01 16:49:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2016-12-26 15:43:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> outcomes measured for 33 participants (5 participants turned out to have low folate levels and were excluded post hoc). The missing data are not likely to impact the effect.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2016-06-01 16:50:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> outcomes measured for 33 participants (5 participants turned out to have low folate levels and were excluded post hoc). The missing data are not likely to impact the effect.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-06-01 16:50:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.09" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> outcomes measured for 33 participants (5 participants turned out to have low folate levels and were excluded post hoc). The missing data are not likely to impact the effect.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Comment: </B>8 participants in the intervention group (oral vitamin B<SUB>12</SUB>) left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2). 3 participants in the control group (intramuscular vitamin B<SUB>12</SUB>) left the trial early due to expired (n = 1) and loss to follow-up (n = 2). The attrition rate is high (18.3%), and the missing data are likely to have an impact on the estimate of effect.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Comment: </B>8 participants in the intervention group (oral vitamin B<SUB>12</SUB>) left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2). 3 participants in the control group (intramuscular vitamin B<SUB>12</SUB>) left the trial early due to expired (n = 1) and loss to follow-up (n = 2). The attrition rate is high (18.3%), and the missing data are likely to have an impact on the estimate of effect.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.09" MODIFIED="2017-10-26 12:40:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION/></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Comment:</B> primary endpoint "improvements in signs and symptoms of anaemia" neither defined nor results reported, no protocol available</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-01 16:49:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> no protocol available</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-16 12:33:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Comment:</B> no protocol</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-10-25 12:16:57 +0200" MODIFIED_BY="[Empty name]" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-01 16:47:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bolaman-2003"><DESCRIPTION><P><B>Comment:</B> none detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-01 16:50:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuzminski-1998"><DESCRIPTION><P><B>Comment:</B> none detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-01-16 12:33:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Saraswathy-2012"><DESCRIPTION><P><B>Comment:</B> none detected</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-01-20 17:00:06 +0100" MODIFIED_BY="Gudrun Paletta" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><SOF_TABLE ID="SOF-01" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES"><TITLE MODIFIED="2018-02-07 19:07:30 +0100" MODIFIED_BY="[Empty name]">Oral versus intramuscular vitamin B<SUB>12</SUB> for vitamin B<SUB>12</SUB> deficiency</TITLE><TABLE COLS="7" ROWS="11"><TR><TD COLSPAN="7" VALIGN="TOP"><P><B>Oral versus intramuscular vitamin B<SUB>12 </SUB>for vitamin B<SUB>12 </SUB>deficiency</B></P></TD></TR><TR><TD COLSPAN="7" VALIGN="TOP"><P><B>Patient:</B> people with vitamin B<SUB>12</SUB> deficiency<BR/><B>Setting: </B>outpatients</P><P><B>Intervention:</B> oral versus IM vitamin B<SUB>12</SUB><BR/></P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>IM vitamin B<SUB>12</SUB></B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Oral vitamin B<SUB>12</SUB></B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>No. of participants<BR/>(trials)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Quality of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Comments</P></TH></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Serum vitamin B<SUB>12 </SUB>levels</B></P><P>Normal value: &gt; 300 pg/mL (&gt; 221 pmol/L)<BR/></P><P>Follow-up: 90 days and 4 months</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Not estimable</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>153 (3)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>low</B><SUP>a</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>1 trial (60 participants) used 1000 &#956;g/day oral or IM vitamin B<SUB>12</SUB> (total dose 15 mg): MD was -11.7 pg/mL (95% CI -29.5 to 6.1) (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>).</P><P>1 trial (33 participants) used 2000 &#956;g/day vitamin B<SUB>12</SUB> (total dose 240 mg) or 1000 &#956;g/day IM vitamin B<SUB>12</SUB> (total dose 9 mg): MD was 680 pg/mL (95% CI 392.7 to 967.3) in favour of oral vitamin B<SUB>12 </SUB>(<LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK>).</P><P>1 trial (60 participants) (using 1000 &#956;g/day oral or IM vitamin B<SUB>12 </SUB>(total dose 90 mg and 15 mg, oral and IM respectively) reported that 27/30 in the IM vitamin B<SUB>12 </SUB>group (90%) and 20/30 in the oral vitamin B<SUB>12 </SUB>group (66.7%) achieved normalisation of serum vitamin B<SUB>12</SUB>, defined as &#8805; 200 pg/mL (<LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK>).</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Clinical signs and symptoms</B></P></TD><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P>Not reported</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Adverse events</B><BR/>Follow-up: 90 days and 3 months</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Not estimable</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>120 (2)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>&#8853;&#8861;&#8861;&#8861;<BR/><B>very</B> <B>low</B><SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> reported no treatment-related adverse events in both the oral and IM vitamin B<SUB>12</SUB> groups.</P><P><LINK REF="STD-Saraswathy-2012" TYPE="STUDY">Saraswathy 2012</LINK> reported that 2/30 participants (6.7%) in the oral vitamin B<SUB>12 </SUB>group left the trial early due to adverse events.</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Health-related quality of life</B></P></TD><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P>Not reported</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Acceptability</B></P></TD><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P>Not reported</P></TD></TR><TR><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P><B>Socioeconomic effects</B></P><P>Follow-up: 90 days</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>See comment</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Not estimable</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>60 (1)</P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>low</B><SUP>c</SUP></P></TD><TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP"><P>Only 1 trial reported data for this outcome (<LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK>). The costs per treatment were USD 80 per person in the oral vitamin B<SUB>12</SUB> group compared with USD 220 per person in the IM group.</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP"><P><B>CI:</B> confidence interval; <B>IM:</B> intramuscular; <B>MD</B>: mean difference</P></TD></TR><TR><TD COLSPAN="7" VALIGN="TOP"><P>GRADE Working Group grades of evidence<BR/><B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/><B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/><B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/><B>Very low quality:</B> We are very uncertain about the estimate.<BR/></P></TD></TR></TABLE><FOOTNOTES><P><SUP>a</SUP>Downgraded by two levels due to serious imprecision (low numbers of trials and participants); see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>.<BR/><SUP>b</SUP>Downgraded by three levels due to risk of bias (performance bias, detection bias) and serious imprecision (low numbers of trials and participants); see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>.<BR/><SUP>c</SUP>Downgraded by two levels due to serious imprecision (low numbers of trials and participants); see <LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>.</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2018-02-19 13:59:01 +0100" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2018-01-25 11:33:53 +0100" MODIFIED_BY="[Empty name]">Overview of trial populations</TITLE><TABLE COLS="9" ROWS="13"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P/></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s) and comparator(s)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Description of power and sample size calculation</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Screened/eligible<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Randomised<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Analysed<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Finishing trial<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Randomised finishing trial<BR/>(%)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Follow-up<BR/>(extended follow-up)<SUP>a</SUP></P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Bolaman 2003</P><P>(parallel RCT)</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: 1000 µg oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8212;</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8212;</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>26</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>26</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>26</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>100</P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>90 days (none)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: 1000 µg IM vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>34</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>34</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>34</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>100</P></TD></TR><TR><TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP"><P>Total:</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>60<SUP>b</SUP></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>60</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>60</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>100</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Kuzminski 1998</P><P>(parallel RCT)</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: 2000 µg oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8212;</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>138</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>100</P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>4 months (none)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: 1000 µg IM vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>100</P></TD></TR><TR><TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP"><P>Total:</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>33<SUP>c</SUP></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>33</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>33</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>100</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Saraswathy 2012</P><P>(parallel RCT)</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: 1000 &#956;g oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>"Sample size was estimated to be 23 in each study arm, assuming equal response of 90% and non inferiority margin of 25% /alpha = 0.25, 1-beta = 80%)"</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>&#8212;</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>30</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>22</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>22</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>73</P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>3 months (none)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: 1000 &#956;g IM vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>30</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>27</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>27</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>90</P></TD></TR><TR><TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP"><P>Total:</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>60</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>49</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>49</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>82</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P><I>Grand total</I></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B><I>All interventions</I></B></P></TH><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP"><P/></TD><TH ALIGN="LEFT" VALIGN="TOP"><P><I>74</I></P></TH><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P/></TD><TH ALIGN="LEFT" VALIGN="TOP"><P><I>66</I></P></TH><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP"><P/></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B><I>All c</I></B><I>omparator<B>s</B></I></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><I>79</I></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><I>76</I></P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B><I>All interventions and c</I></B><I>omparator<B>s</B></I></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><I>153</I></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><I>142</I></P></TH></TR></TABLE><FOOTNOTES><P>&#8212; denotes not reported</P><P>C: comparator; I: intervention; IM: intramuscular; RCT: randomised controlled trial</P><P><SUP>a</SUP>Follow-up under randomised conditions until end of trial (= duration of intervention + follow-up postintervention or identical to duration of intervention); extended follow-up refers to follow-up of participants once the original trial was terminated as specified in the power calculation.<BR/><SUP>b</SUP>Of 70 participants enrolled in the trial, 10 were excluded because of failure to appear for follow-up after 10 days of treatment.<BR/><SUP>c</SUP>38 participants were randomised; after completion of the trial 5 participants were judged to have primary folate deficiency rather than vitamin B<SUB>12</SUB> deficiency and were excluded from the final analysis.<BR/></P></FOOTNOTES></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2018-02-19 14:02:17 +0100" MODIFIED_BY="[Empty name]"><COMPARISON ID="CMP-001" MODIFIED="2018-02-19 14:02:17 +0100" MODIFIED_BY="[Empty name]" NO="1"><NAME>Oral versus intramuscular vitamin B<SUB>12</SUB></NAME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2018-02-19 14:02:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="44" TOTAL_2="49" UNITS="pg/mL" WEIGHT="0.0" Z="0.0"><NAME>Serum vitamin B<SUB>12</SUB> levels</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><CONT_DATA CI_END="6.114018719046921" CI_START="-29.5140187190469" EFFECT_SIZE="-11.699999999999989" ESTIMABLE="YES" MEAN_1="213.8" MEAN_2="225.5" MODIFIED="2018-02-19 14:02:17 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SD_1="30.2" SD_2="40.2" SE="9.08895207236542" STUDY_ID="STD-Bolaman-2003" TOTAL_1="26" TOTAL_2="34" WEIGHT="0.0"/><CONT_DATA CI_END="967.2738645601978" CI_START="392.72613543980225" EFFECT_SIZE="680.0" ESTIMABLE="YES" MEAN_1="1005.0" MEAN_2="325.0" MODIFIED="2018-02-19 14:02:17 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="595.0" SD_2="165.0" SE="146.5709915213633" STUDY_ID="STD-Kuzminski-1998" TOTAL_1="18" TOTAL_2="15" WEIGHT="0.0"/></CONT_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="1.1860469361943708" CI_START="0.7701850003976849" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9557591537749113" ESTIMABLE="NO" EVENTS_1="38" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.0741018759817635" LOG_CI_START="-0.11340494365661319" LOG_EFFECT_SIZE="-0.019651533837424837" METHOD="MH" MODIFIED="2017-12-04 04:43:31 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.6812004390960764" Q="0.0" RANDOM="YES" SCALE="9.05" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="48" TOTAL_2="44" WEIGHT="0.0" Z="0.41082557569484573"><NAME>Number of participants with normalisation of serum vitamin B<SUB>12</SUB> deficiency</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><DICH_DATA CI_END="1.9531587284746612" CI_START="0.9906098364776051" EFFECT_SIZE="1.3909774436090225" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.29073753878171216" LOG_CI_START="-0.004097363909856207" LOG_EFFECT_SIZE="0.143320087435928" MODIFIED="2016-12-26 11:11:39 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.1731874812973334" STUDY_ID="STD-Kuzminski-1998" TOTAL_1="18" TOTAL_2="14" VAR="0.029993903678114206" WEIGHT="0.0"/><DICH_DATA CI_END="0.9798369368339047" CI_START="0.5599879167304269" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="-0.00884619300707836" LOG_CI_START="-0.25182134398293393" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2016-12-23 09:09:13 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.14272480642961255" STUDY_ID="STD-Saraswathy-2012" TOTAL_1="30" TOTAL_2="30" VAR="0.020370370370370372" WEIGHT="0.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2017-10-25 17:14:15 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="902.3470936079397" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0"><NAME>Adverse events</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><DICH_DATA CI_END="99.95416281504153" CI_START="0.25011464551267176" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9998008859974516" LOG_CI_START="-0.6018608773254143" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2017-01-13 07:16:02 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="1.5282289982092807" STUDY_ID="STD-Saraswathy-2012" TOTAL_1="30" TOTAL_2="30" VAR="2.335483870967742" WEIGHT="0.0"/></DICH_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.5048627312156021" CI_START="-0.3048627312155992" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000143" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2017-10-26 12:02:39 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.6283107833371371" Q="0.0" RANDOM="YES" SCALE="2.7" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="26" TOTAL_2="34" UNITS="g/dL" WEIGHT="0.0" Z="0.48410580510962054"><NAME>Haemoglobin</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><CONT_DATA CI_END="0.504862731215602" CI_START="-0.3048627312155992" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="13.8" MEAN_2="13.7" MODIFIED="2016-01-01 20:57:45 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="0.7" SD_2="0.9" SE="0.2065664136734686" STUDY_ID="STD-Bolaman-2003" TOTAL_1="26" TOTAL_2="34" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="1.8911244981500617" CI_START="-1.8576324273192277" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.016746035415416895" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2017-10-26 12:09:36 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.9860292191970758" Q="0.0" RANDOM="YES" SCALE="25.01" SORT_BY="YEAR" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="44" TOTAL_2="49" UNITS="fL" WEIGHT="0.0" Z="0.017510671911031186"><NAME>Mean corpuscular volume</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><CONT_DATA CI_END="3.7964643278543484" CI_START="-5.796464327854348" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="90.0" MEAN_2="91.0" MODIFIED="2017-10-26 12:09:03 +0200" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="7.0" SD_2="7.0" SE="2.447220645730354" STUDY_ID="STD-Kuzminski-1998" TOTAL_1="18" TOTAL_2="15" WEIGHT="0.0"/><CONT_DATA CI_END="2.236299546896388" CI_START="-1.8362995468963823" EFFECT_SIZE="0.20000000000000284" ESTIMABLE="YES" MEAN_1="86.9" MEAN_2="86.7" MODIFIED="2017-10-26 12:09:20 +0200" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="3.9" SD_2="4.1" SE="1.038947431156111" STUDY_ID="STD-Bolaman-2003" TOTAL_1="26" TOTAL_2="34" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="1.3045993231012107" CI_START="-4.5045993231012105" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2017-10-26 12:13:39 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.28029935406811124" Q="0.0" RANDOM="YES" SCALE="8.02" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="18" TOTAL_2="15" UNITS="&#956;mol/L" WEIGHT="0.0" Z="1.0796471479983245"><NAME>Total homocysteine</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><CONT_DATA CI_END="1.3045993231012107" CI_START="-4.5045993231012105" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="12.2" MODIFIED="2016-01-02 06:44:44 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="4.4" SD_2="4.1" SE="1.4819656616204784" STUDY_ID="STD-Kuzminski-1998" TOTAL_1="18" TOTAL_2="15" WEIGHT="0.0"/></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="8.755750985087005" CI_START="-200.755750985087" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-95.99999999999999" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2017-10-26 12:16:15 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.07247142255545143" Q="0.0" RANDOM="YES" SCALE="207.62" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="18" TOTAL_2="15" UNITS="nmo/L" WEIGHT="0.0" Z="1.7961452306578483"><NAME>Serum methylmalonic acid</NAME><GROUP_LABEL_1>Oral vitamin B12</GROUP_LABEL_1><GROUP_LABEL_2>Intramuscular vitamin B12</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IM vitamin B12</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours oral vitamin B12</GRAPH_LABEL_2><CONT_DATA CI_END="8.75575098508699" CI_START="-200.755750985087" EFFECT_SIZE="-96.0" ESTIMABLE="YES" MEAN_1="169.0" MEAN_2="265.0" MODIFIED="2016-07-21 15:47:10 +0200" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="90.0" SD_2="190.0" SE="53.44779384283945" STUDY_ID="STD-Kuzminski-1998" TOTAL_1="18" TOTAL_2="15" WEIGHT="0.0"/></CONT_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2018-02-26 13:29:56 +0100" MODIFIED_BY="[Empty name]"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2018-02-26 13:29:56 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Study flow diagram.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2018-02-19 13:59:06 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not measured in some studies).</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2018-02-19 13:59:06 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not measure that particular outcome).</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK/><APPENDICES MODIFIED="2018-02-19 14:01:06 +0100" MODIFIED_BY="[Empty name]"><APPENDIX ID="APP-01" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="1"><TITLE MODIFIED="2013-02-28 14:54:13 +0100" MODIFIED_BY="Karla Bergerhoff">Search strategies</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="1" ROWS="12"><TR><TH VALIGN="TOP"><P><B>Cochrane Library</B></P></TH></TR><TR><TD VALIGN="TOP"><P>1. [mh "Vitamin B 12"]</P><P>2. ((vitamin* or vit or coenzym*) near/1 (b12 or "b 12" or b12? or "b 12?")):ti,ab</P><P>3. (cobalamin* or hydrox?cobalamin* or c?anocobalamin* or methylcobalamin* or adenosylcobalamin* or dibencozid* or cobamamid* or cobamid*):ti,ab</P><P>4. {or #1-#3}</P><P>5. [mh "Vitamin B 12 Deficiency"]</P><P>6. ((b12 or "b 12" or b12? or "b 12?" or cobalamin* or cyanocobalamin) near/3 deficien*):ti,ab</P><P>7. #5 or #6</P><P>8. #4 and #7 [Publication Year from 2005 to 2017]</P></TD></TR><TR><TH VALIGN="TOP"><P><B>MEDLINE (Ovid SP)</B></P></TH></TR><TR><TD VALIGN="TOP"><P>1. exp Vitamin B 12/</P><P>2. ((vitamin* or vit or coenzym*) adj1 (b12? or "b 12?")).tw.</P><P>3. (cobalamin* or hydrox?cobalamin* or c?anocobalamin* or methylcobalamin* or adenosylcobalamin* or dibencozid* or cobamamid* or cobamid*).tw.</P><P>4. or/1-3</P><P>5. exp Vitamin B 12 Deficiency/</P><P>6. ((b12? or "b 12?" or cobalamin* or cyanocobalamin) adj3 deficien*).tw.</P><P>7. or/5-6</P><P>8. 4 and 7</P><P><I>[9-19: Cochrane Handbook 2008 RCT filter - sensitivity max. version]</I></P><P>9. randomized controlled trial.pt.</P><P>10. controlled clinical trial.pt.</P><P>11. randomi?ed.ab.</P><P>12. placebo.ab.</P><P>13. drug therapy.fs.</P><P>14. randomly.ab.</P><P>15. trial.ab.</P><P>16. groups.ab.</P><P>17. or/9-16</P><P>18. exp animals/ not humans/</P><P>19. 17 not 18</P><P>20. 8 and 19</P><P>21. (200412?? or 2005* or 2006* or 2007* or 2008* or 2009 or 201*).dc.</P><P>22. 20 and 21</P></TD></TR><TR><TH VALIGN="TOP"><P><B>Embase (Ovid SP)</B></P></TH></TR><TR><TD VALIGN="TOP"><P>1. cobalamin derivative/</P><P>2. hydroxocobalamin/</P><P>3. methylcobalamin/</P><P>4. cyanocobalamin/</P><P>5. cobamamide/</P><P>6. cobalamin/</P><P>7. ((vitamin* or vit or coenzym*) adj1 (b12? or "b 12?")).tw.</P><P>8. (cobalamin* or hydrox?cobalamin* or c?anocobalamin* or methylcobalamin* or adenosylcobalamin* or dibencozid* or cobamamid* or cobamid*).tw.</P><P>9. or/1-8</P><P>10. cyanocobalamin deficiency/</P><P>11. ((b12? or "b 12?" or cobalamin* or cyanocobalamin) adj3 deficien*).tw.</P><P>12. or/10-11</P><P>13. 9 and 12</P><P><I>[13 </I><LINK REF="REF-Wong-2006" TYPE="REFERENCE">Wong 2006</LINK><I> "sound treatment studies" filter &#8211; BS version]</I></P><P>14. random*.tw. or clinical trial*.mp. or exp health care quality/</P><P>15. 13 and 14</P><P>16. (200412?? or 2005* or 2006* or 2007* or 2008* or 2009 or 201*).dc.</P><P>17. 15 and 16</P></TD></TR><TR><TH VALIGN="TOP"><P>LILACS (iAHx)</P></TH></TR><TR><TD VALIGN="TOP"><P>(MH:" Vitamin B 12" OR ((vitamin$ OR coenzym$ OR coenzim$) AND (B12 OR "B 12")) OR (cobalamin$ OR hydroxicobalamin$ OR hydroxocobalamin$ hidroxicobalamin$ OR hidroxocobalamin$ OR cyanocobalamin$ OR cianocobalamin$ OR methylcobalamin$ OR metilcobalamin$ OR adenosylcobalamin$ OR adenosilcobalamin$ OR dibencozid$ OR cobamamid$ OR cobamid$)) AND (MH: "Vitamin B 12 Deficiency" OR ((B12 OR "B 12" OR cobalamin$ OR cyanocobalamin$ OR cianocobalamin$) AND deficien$))</P><P>+ Filter "Controlled Clinical Trial"</P></TD></TR><TR><TH VALIGN="TOP"><P>ClinicalTrials.gov (Expert search)</P></TH></TR><TR><TD VALIGN="TOP"><P>( hydroxocobalamin OR hydroxicobalamin OR methylcobalamin OR cyanocobalamin OR cobamamide OR cobalamin OR dibencozid OR adenosylcobalamin OR cobamide OR "vitamin B12" OR "vitamin B 12" OR "coenzym B12" OR "coenzym B 12" ) AND ( B12 OR "B 12" OR cobalamin OR cyanocobalamin ) AND ( deficiency OR deficiencies OR deficient ) AND EXACT "Interventional" [STUDY-TYPES]</P></TD></TR><TR><TH VALIGN="TOP"><P>ICTRP Search Portal (Standard search)</P></TH></TR><TR><TD VALIGN="TOP"><P>deficien* AND vitamin B12 OR</P><P>deficien* AND vitamin B 12 OR</P><P>vitamin B12 deficiency OR</P><P>vitamin B 12 deficiency OR</P><P>deficien* AND cobalamin* OR</P><P>deficien* AND cyanocobalamin*</P></TD></TR></TABLE><P/></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="2"><TITLE MODIFIED="2015-06-09 14:07:40 +0200" MODIFIED_BY="Gudrun Paletta">Description of interventions</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="3" ROWS="4"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s)<BR/>(route, frequency, total dose/day)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Comparator(s)<BR/>(route, frequency, total dose/day)<BR/></P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Oral: 1000 µg cyanocobalamin (ampoule mixed with 20 mL fruit juice) self administered once daily for 10 days; after 10 days, once a week for 4 weeks and then once a month for life</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Intramuscular: 1000 µg cyanocobalamin (ampoule, injection by a nurse into the gluteus muscle) once daily for 10 days; after 10 days, once a week for 4 weeks and then once a month for life<BR/></P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Oral: 2000 µg cyanocobalamin (two 1000 µg tablets) with breakfast daily for 4 months</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Intramuscular: 1000 µg cyanocobalamin on days 1, 3, 7, 10, 14, 21, 30, 60, and 90 (injection by a nurse)</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Saraswathy 2012</B></P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Oral: 1000 &#956;g of vitamin B<SUB>12</SUB> daily for 3 months</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Intramuscular: 1000 &#956;g of vitamin B<SUB>12</SUB> once daily for a week followed by once a week for 8 weeks</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2018-02-19 14:00:56 +0100" MODIFIED_BY="[Empty name]" NO="3"><TITLE MODIFIED="2015-06-09 14:09:08 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics (I)</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 14:00:56 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="10" ROWS="8"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s) and comparator(s)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Duration of intervention<BR/>(duration of follow-up)<BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Description of participants</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial period<BR/>(year to year)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Country</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Setting</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Ethnic groups<BR/>(%)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Duration of vitamin B<SUB>12</SUB> deficiency<BR/>(mean years (SD))</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Vitamin B<SUB>12</SUB> levels (mean pg/mL (SD))</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>90 days (90 days)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>People with megaloblastic anaemia due to vitamin B<SUB>12</SUB> deficiency (defined as serum vitamin B<SUB>12</SUB> level &lt; 160 pg/mL)<BR/><BR/></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1999 to 2003<BR/><BR/></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Turkey</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Hospital<BR/></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>72.9 (54.8)<BR/><BR/></P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>90 days (90 days)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>70.2 (59.1)<BR/><BR/></P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>4 months (4 months)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>People with newly diagnosed vitamin B<SUB>12</SUB> deficiency (defined as serum vitamin B<SUB>12</SUB> level &lt; 160 pg/mL)<BR/><BR/></P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>1993 to 1996</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>USA</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Ambulatory care centres</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>White: 97</P><P>Latina: 3</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>93 (46)<BR/><BR/></P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>90 days (4 months)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>95 (92)</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3 months (3 months)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Consecutive patients with vitamin B<SUB>12</SUB> deficiency (serum vitamin B<SUB>12</SUB> level &lt; 200 pg/mL)</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>2009 to 2010</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>South India</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>A tertiary care hospital</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>149.8 (37.6)<BR/><BR/></P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>9 weeks (3 months)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>146.0 (42.1)<BR/><BR/></P></TD></TR><TR><TD COLSPAN="10" VALIGN="TOP"><P>- denotes not reported</P><P>C: comparator; I: intervention; SD: standard deviation</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-04" MODIFIED="2018-02-19 14:01:06 +0100" MODIFIED_BY="[Empty name]" NO="4"><TITLE MODIFIED="2015-06-09 14:09:08 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics (II)</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 14:01:06 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="10" ROWS="8"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s) and comparator(s)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Sex<BR/>(female %)<BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Age<BR/>(mean years (SD)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>MCV (mean fL (SD))</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Haemoglobin (mean g/dL (SD))</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Total homocysteine (mean &#956;mol/L (SD))</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Serum methylmalonic acid (mean nmol/L (SD))</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Comedications/Cointerventions</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Comorbidities</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>39</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>60 (15)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>112.3 (11.4)<BR/><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>8.4 (2.1)<BR/><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18/26 participants with upper GI endoscopy</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Atrophic gastritis: 5<BR/>Chronic antral gastritis: 5<BR/>Chronic pangastritis: 3<BR/>Enterogastric reflux: 2<BR/>Alkaline reflux: 2</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>50</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>64 (10)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>114.8 (10.9)<BR/><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>8.3 (2.3)<BR/><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>27/34 participants with upper GI endoscopy</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Atrophic gastritis: 9<BR/>Chronic antral gastritis: 2<BR/>Chronic pangastritis: 4<BR/>Enterogastric reflux: 2<BR/>Alkaline reflux: 4<BR/>Erosive gastritis: 1</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>67</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>72 (11)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>100 (12)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>37.2 (44.9)<BR/><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3850 (6930)<BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Atrophic gastritis: 7 (3 unclear)<BR/>Pernicious anaemia: 5<BR/>Inadequate dietary protein intake: 3</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>87</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>71 (15)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>102 (11)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>40.0 (26.2)<BR/><BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>3630 (7040)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Atrophic gastritis: 7<BR/>Pernicious anaemia: 2<BR/>Inadequate dietary protein intake: 2<BR/>Prior ileal resection: 1<BR/>Prior gastric stapling: 1</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>36.7</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>38.6 (14.8)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>92.8 (14.3)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>11.7 (2.4)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>16.7</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>44.3 (9.3)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>89.4 (16.3)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>12.4 (2.7)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD></TR><TR><TD COLSPAN="10" VALIGN="TOP"><P>- denotes not reported</P><P>C: comparator; GI: gastrointestinal tract; I: intervention; MCV: mean corpuscular volume; SD: standard deviation</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-05" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="5"><TITLE MODIFIED="2016-03-02 16:41:23 +0100" MODIFIED_BY="[Empty name]">Matrix of trial endpoints (publications and trial documents)</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="5" ROWS="11"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Endpoints quoted in trial document(s)<BR/>(ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)<SUP>a</SUP></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial results/<BR/>publications available<BR/>in trial register<BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Endpoints quoted in publication(s)<SUP>b,c</SUP><BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Endpoints quoted in abstract of publication(s)<SUP>b,c</SUP></P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP"><P><B>Source: </B>N/T</P></TD><TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>No full publication</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Primary outcome measure:</B> proportion of participants with serum vitamin B<SUB>12</SUB> normalisation (&#8805; 200 pg/mL) after 60 days of treatment</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Secondary outcome measure: </B>compliance: ensured by pill/ampoule count and verification of injection records</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Other outcome measure(s):</B> -</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP"><P><B>Source: </B>N/T</P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Primary outcome measure(s):</B> -</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Primary outcome measure(s):</B> -</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Secondary outcome measure(s):</B> -</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Secondary outcome measure(s):</B> -</P><P/></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Other outcome measure(s):</B> haemoglobin level, improvements in signs and symptoms of anaemia; response to therapy (detection of reticulocytosis between days 5 and 10, and recovery of the haematologic parameters on complete blood counts and peripheral blood smears at days 10, 30, and 90 of treatment); tolerability - adverse events (assessed by a haematologist at days 0, 30, and 90 using laboratory tests, e.g. serum potassium level, eosinophilia on blood smear, and patient interviews); costs (costs of the study drug and of the injections); serum vitamin B<SUB>12</SUB> levels; serum autoantibodies to gastric parietal cells; cognitive function (Mini-Mental State Examination); vibration threshold; neurologic sensory assessment (soft-touch, pinprick examination)</P><P/></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Other outcome measure(s):</B> therapeutic effectiveness (haematologic parameters on days 0, 10, 30, and 90); serum vitamin B<SUB>12</SUB> (on days 0 and 90); cognitive function, vibration threshold; neurologic sensory assessment; tolerability</P><P><BR/><BR/></P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="3" VALIGN="TOP"><P><B>Source:</B> N/T</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Primary outcome measure(s):</B> -</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Primary outcome measure(s):</B> -</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Secondary outcome measure(s):</B> -</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Secondary outcome measure(s):</B> -</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Other outcome measure(s):</B> serum vitamin B<SUB>12</SUB> levels, serum folate levels, serum anti-intrinsic factor antibodies, unsaturated serum cobalamin-binding capacity, serum methylmalonic acid levels, serum homocysteine levels, serum pepsinogen I levels, neurologic symptoms, haematocrit, mean corpuscular volume</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P><B>Other outcome measure(s):</B> therapeutic effectiveness: haematologic and neurologic improvement and changes in serum levels of cobalamin (normal: 200 to 900 pg/mL), methylmalonic acid (normal: 73 to 271 nmol/L), and homocysteine (normal: 5.1 to 13.9 µmol/L)<BR/></P></TD></TR><TR><TD COLSPAN="5" VALIGN="TOP"><P>- denotes not reported<BR/>EMA: European Medicines Agency; FDA: US Food and Drug Administration; N/T: no trial document available<BR/></P><P><SUP>a</SUP>Trial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturer's websites, trial registers).<BR/><SUP>b</SUP>Publication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents or multiple reports of a primary trial).<BR/><SUP>c</SUP>Other outcome measures refers to all outcomes not specified as primary or secondary outcome measures.<BR/></P><P/></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-06" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="6"><TITLE MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]">High risk of outcome reporting bias according to Outcome Reporting Bias In Trials (ORBIT) classification</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="6" ROWS="5"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Outcome</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>High risk of bias<BR/>(category A)<SUP>a</SUP></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>High risk of bias<BR/>(category D)<SUP>b</SUP></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>High risk of bias<BR/>(category E)<SUP>c</SUP></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>High risk of bias<BR/>(category G)<SUP>d</SUP></P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD COLSPAN="6" VALIGN="TOP"><P>N/A: not applicable</P><P><SUP>a</SUP>Clear that outcome was measured and analysed; trial report states that outcome was analysed but only reports that result was not significant.<BR/>(Classification 'A', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)<BR/><SUP>b</SUP>Clear that outcome was measured and analysed; trial report states that outcome was analysed but no results reported.<BR/>(Classification 'D', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)<BR/><SUP>c</SUP>Clear that outcome was measured; clear that outcome was measured but not necessarily analysed; judgement says likely to have been analysed but not reported due to non-significant results.<BR/>(Classification 'E', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)<BR/><SUP>d</SUP>Unclear whether the outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but not reported on the basis of non-significant results.<BR/>(Classification 'G', table 2, <LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>)</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-07" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="7"><TITLE MODIFIED="2016-11-07 17:32:36 +0100" MODIFIED_BY="[Empty name]">Definition of endpoint measurement<SUP>a</SUP></TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="8" ROWS="5"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Definition of vitamin <B>B<SUB>12 </SUB>deficiency </B><BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Therapeutic efficacy</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Adverse events</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Health-related quality of life</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Acceptability</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Socioeconomic effects</P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Serum vitamin B<SUB>12</SUB> concentrations &lt; 160 pg/mL, megaloblastic anaemia, mean corpuscular volume &gt; 94 fL (IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Response to therapy (detection of reticulocytosis between days 5 and 10, and recovery of the haematologic parameters on complete blood counts and peripheral blood smears at days 10, 30, and 90 of treatment)<BR/>(IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Cognitive function (Mini-Mental State Examination)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Tolerabilty - adverse events (assessed by a haematologist at days 0, 30, and 90 using laboratory tests, e.g. serum potassium level, eosinophilia on blood smear, and participant interviews)<BR/>(IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Tolerabilty - adverse events (assessed by a haematologist at days 0, 30, and 90 using laboratory tests, e.g. serum potassium level, eosinophilia on blood smear, and participant interviews)<BR/>(IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Costs of the study drug and of the injections<BR/>(IO)</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Serum vitamin B<SUB>12</SUB> concentrations &lt; 160 pg/mL<BR/>(IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Haematologic and neurologic improvement and changes in serum levels of vitamin B<SUB>12</SUB> (normal: 200 to 900 pg/mL), methylmalonic acid (normal: 73 to 271 nmol/L), and homocysteine (normal: 5.1 to 13.9 µmol/L)<BR/>(IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>"Neurologic improvement"<BR/>(IO)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Serum vitamin B<SUB>12</SUB> concentrations &lt; 200 pg/mL<BR/>(IO)<BR/></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Proportion of participants in each treatment arm in whom vitamin B<SUB>12</SUB> levels were normalised (&#8805; 200 ng/mL) at 3 months after initial treatment</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/I</P></TD></TR><TR><TD COLSPAN="8" VALIGN="TOP"><P>AO: adjudicated outcome measurement; IO: investigator-assessed outcome measurement; N/I: not investigated; SO: self reported outcome measurement</P><P><SUP>a</SUP>In addition to definition of endpoint measurement, description of who measured the outcome (AO: adjudicated outcome measurement; IO: investigator-assessed outcome measurement; SO: self reported outcome measurement).</P><P/></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-08" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="8"><TITLE MODIFIED="2016-03-02 16:41:54 +0100" MODIFIED_BY="[Empty name]">Adverse events (I)</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="9" ROWS="8"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s) and comparator(s)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants included in analysis<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Deaths<BR/>(N)<BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Deaths<BR/>(%)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with adverse events<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with adverse events<BR/>(%)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with severe/serious adverse events<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with severe/serious adverse events<BR/>(%)</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>26<SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>34<SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18<SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15<SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>22<SUP>c</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>27<SUP>d</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD COLSPAN="9" VALIGN="TOP"><P>- denotes not reported</P><P>C: comparator; I: intervention</P><P><SUP>a</SUP>Ten participants in <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> left the trial early, and the group assignment of the 10 participants was not reported ("no treatment related adverse events were reported in either treatment group").</P><P><SUP>b</SUP>Five participants in <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> were judged to have deficiency of primary folate rather than of cobalamin, therefore they were excluded from the data analysis.</P><P><SUP>c</SUP>Eight participants in this group left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2).</P><P><SUP>d</SUP>Three participants in this group left the trial early due to expired (n = 1) and loss to follow-up (n = 2).</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-09" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="9"><TITLE MODIFIED="2016-03-02 16:41:54 +0100" MODIFIED_BY="[Empty name]">Adverse events (II)</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="9" ROWS="8"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s) and comparator(s)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants included in analysis<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants discontinuing study due to adverse events<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants discontinuing study due to adverse events<BR/>(%)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants hospitalised<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants hospitalised<BR/>(%)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with outpatient treatment<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with outpatient treatment<BR/>(%)</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>26<SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>34<SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18<SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15<SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>22<SUP>c</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>2</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>6.7</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>27<SUP>d</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>0</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD COLSPAN="9" VALIGN="TOP"><P>- denotes not reported</P><P>C: comparator; I: intervention</P><P><SUP>a</SUP>Ten participants in <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> left the trial early, and the group assignment of the 10 participants was not reported.</P><P><SUP>b</SUP>Five participants in <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> were judged to have deficiency of primary folate rather than of cobalamin, therefore they were excluded from the data analysis.</P><P><SUP>c</SUP>Eight participants in this group left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2).</P><P><SUP>d</SUP>Three participants in this group left the trial early due to expired (n = 1) and loss to follow-up (n = 2).<BR/></P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-10" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="10"><TITLE MODIFIED="2016-03-02 16:41:54 +0100" MODIFIED_BY="[Empty name]">Adverse events (III)</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="6" ROWS="8"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Intervention(s) and comparator(s)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants included in analysis<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with specific adverse events<BR/>(description)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with specific adverse events<BR/>(N)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Participants with specific adverse events<BR/>(%)</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>26<SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>34<SUP>a</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>18<SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>15<SUP>b</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>I: oral vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>22<SUP>c</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>C: intramuscular vitamin B<SUB>12</SUB></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>27<SUP>d</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>-</P></TD></TR><TR><TD COLSPAN="6" VALIGN="TOP"><P>- denotes not reported</P><P>C: comparator; I: intervention</P><P><SUP>a</SUP>Ten participants in <LINK REF="STD-Bolaman-2003" TYPE="STUDY">Bolaman 2003</LINK> left the trial early, and the group assignment of the 10 participants was not reported.</P><P><SUP>b</SUP>Five participants in <LINK REF="STD-Kuzminski-1998" TYPE="STUDY">Kuzminski 1998</LINK> were judged to have deficiency of primary folate rather than of cobalamin, therefore they were excluded from the data analysis.</P><P><SUP>c</SUP>Eight participants in this group left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2).</P><P><SUP>d</SUP>Three participants in this group left the trial early due to expired (n = 1) and loss to follow-up (n = 2).</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-11" MODIFIED="2018-02-14 15:56:03 +0100" MODIFIED_BY="[Empty name]" NO="11"><TITLE MODIFIED="2016-03-02 16:41:54 +0100" MODIFIED_BY="[Empty name]">Survey of study investigators providing information on included trials</TITLE><APPENDIX_BODY MODIFIED="2018-02-14 15:56:03 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="5" ROWS="5"><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Trial ID</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Date trial author contacted<BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Date trial author replied<BR/></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Date trial author asked for additional information<BR/>(short summary)</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Date trial author provided data<BR/>(short summary)<BR/></P></TH></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Bolaman 2003</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>18 March 2016</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No reply</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Kuzminski 1998</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>18 March 2016</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No reply</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TH ALIGN="LEFT" VALIGN="TOP"><P>Saraswathy 2012</P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>23 December 2016</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No reply</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="5" VALIGN="TOP"><P>N/A: not applicable</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-12" MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]" NO="12"><TITLE MODIFIED="2017-12-04 04:40:02 +0100" MODIFIED_BY="[Empty name]">Checklist to aid consistency and reproducibility of GRADE assessments</TITLE><APPENDIX_BODY MODIFIED="2018-02-19 13:59:02 +0100" MODIFIED_BY="[Empty name]"><TABLE COLS="8" ROWS="31"><TR><TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM"><P/></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Serum vitamin B<SUB>12</SUB> level </B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Clinical signs and symptoms of vitamin B<SUB>12</SUB> deficiency</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Adverse events</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P><B>Health-related quality of life</B></P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Acceptability</P></TH><TH ALIGN="LEFT" VALIGN="TOP"><P>Socioeconomic effects</P></TH></TR><TR><TH ALIGN="LEFT" ROWSPAN="9" VALIGN="TOP"><P>Trial limitations<BR/>(risk of bias)<SUP>a</SUP></P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Was random sequence generation used (i.e. no potential for selection bias)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" ROWSPAN="29" VALIGN="TOP"><P>N/R</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD><TD ALIGN="LEFT" ROWSPAN="29" VALIGN="TOP"><P>N/R</P></TD><TD ALIGN="LEFT" ROWSPAN="29" VALIGN="TOP"><P>N/R</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was allocation concealment used (i.e. no potential for selection bias)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was there blinding of participants and personnel (i.e. no potential for performance bias) or outcome not likely to be influenced by lack of blinding?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was there blinding of outcome assessment (i.e. no potential for detection bias) or was outcome measurement not likely to be influenced by lack of blinding?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was an objective outcome used?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>No (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Were more than 80% of participants enrolled in trials included in the analysis (i.e. no potential reporting bias)?<SUP>e</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Were data reported consistently for the outcome of interest (i.e. no potential selective reporting)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>No other biases reported (i.e. no potential for other bias)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Did the trials end as scheduled (i.e. not stopped early)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="5" VALIGN="TOP"><P>Inconsistency<SUP>b</SUP></P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Point estimates did not vary widely?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>To what extent did confidence intervals overlap (substantial: all confidence intervals overlap at least one of the included studies point estimate; some: confidence intervals overlap but not all overlap at least one point estimate; no: at least one outlier: where the confidence intervals of some<BR/>of the studies do not overlap with those of most included studies)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was the direction of effect consistent?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>What was the magnitude of statistical heterogeneity (as measured by I²): low (I² &lt; 40%), moderate (I² 40% to 60%), high (I² &gt; 60%)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was the test for heterogeneity statistically significant (P &lt; 0.1)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="5" VALIGN="TOP"><P>Indirectness<SUP>a</SUP></P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Were the populations in the included studies applicable to the decision context?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Were the interventions in the included studies applicable to the decision context?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Highly applicable</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Highly applicable</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Highly applicable</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was the included outcome not a surrogate outcome?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was the outcome time frame sufficient?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Sufficient</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Sufficient</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Sufficient</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Were the conclusions based on direct comparisons?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP"><P>Imprecision<SUP>c</SUP></P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Was the confidence interval for the pooled estimate not consistent with benefit and harm?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>What is the magnitude of the median sample size (high: 300 participants, intermediate: 100 to 300 participants, low: &lt; 100 participants)?<SUP>e</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Low (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Low (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Low (&#8595;)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>What was the magnitude of the number of included studies (large: &gt; 10 studies, moderate: 5 to 10 studies, small: &lt; 5 studies)?<SUP>e</SUP></P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Small (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Small (&#8595;)</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Small (&#8595;)</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was the outcome a common event (e.g. occurs more than 1/100)?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TH ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP"><P>Publication bias<SUP>d</SUP></P></TH><TD ALIGN="LEFT" VALIGN="TOP"><P>Was a comprehensive search conducted?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Was grey literature searched?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>Were no restrictions applied to study selection on the basis of language?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Yes</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>There was no industry influence on studies included in the review?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>Unclear</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>There was no evidence of funnel plot asymmetry?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD ALIGN="LEFT" VALIGN="TOP"><P>There was no discrepancy in findings between published and unpublished trials?</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD><TD ALIGN="LEFT" VALIGN="TOP"><P>N/A</P></TD></TR><TR><TD COLSPAN="8" VALIGN="TOP"><P>(&#8595;): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of findings' table(s); N/A: not applicable; N/R: not reported</P><P><SUP>a</SUP>Questions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials.<BR/><SUP>b</SUP>Questions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I².<BR/></P><P><SUP>c</SUP>When judging the width of the confidence interval, it is recommended that a clinical decision threshold be used to assess whether the imprecision is clinically meaningful.<BR/><SUP>d</SUP>Questions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry, and discrepancies between published and unpublished trials.<BR/><SUP>e</SUP>Depends on the context of the systematic review area.</P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS MODIFIED="2016-02-28 13:31:17 +0100" MODIFIED_BY="[Empty name]"><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;3 completed trials (3 publications) included in qualitative synthesis&lt;/p&gt;" WIDTH="296"><FLOWCHARTBOX TEXT="&lt;p&gt;2 included trials (2 publications) from previous version (Issue 3, 2005) of review&lt;/p&gt;" WIDTH="259"/><FLOWCHARTBOX TEXT="&lt;p&gt;6 trials (8 publications/records) included&lt;/p&gt;" WIDTH="319"><FLOWCHARTBOX TEXT="&lt;p&gt;No additional publications identified through handsearching of reference lists of included trials, systematic reviews/meta-analyses, and health technology assessment reports&lt;/p&gt;" WIDTH="297"><FLOWCHARTBOX TEXT="&lt;p&gt;39 full-text articles/records assessed for eligibility&lt;/p&gt;" WIDTH="179"><FLOWCHARTBOX TEXT="&lt;p&gt;1666 records screened&lt;/p&gt;" WIDTH="152"><FLOWCHARTBOX TEXT="&lt;p&gt;1666 records after duplicates removed&lt;/p&gt;" WIDTH="306"><FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;For this update &lt;/span&gt;2328 records were identified through database searching&lt;/p&gt;&lt;p&gt;Cochrane Library: 234&lt;br&gt;MEDLINE: 924&lt;br&gt;Embase: 998&lt;br&gt;LILACS: 10&lt;br&gt;WHO ICTRP: 71&lt;br&gt;ClinicalTrials.gov: 91&lt;/p&gt;" WIDTH="264"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;1627 non-relevant records excluded (title/abstract)&lt;/p&gt;" WIDTH="229"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;31 full-text articles excluded&lt;/p&gt;&lt;p&gt;Participants had borderline &lt;br&gt;vitamin B&lt;sub&gt;12&lt;/sub&gt; deficiency (3)&lt;br&gt;All participants received multivitamin tablets (1)&lt;br&gt;Single-arm trial (2)&lt;br&gt;Vitamin B&lt;sub&gt;12&lt;/sub&gt; versus placebo (1)&lt;br&gt;Non-randomised trial or commentary/review/letter/case report (22)&lt;br&gt;Systematic reviews/meta-analysis (1)&lt;br&gt;Cost analysis (1)&lt;/p&gt;" WIDTH="269"/></FLOWCHARTBOX></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;2 potentially relevant ongoing trials (4 publications)&lt;br&gt;1 potentially relevant trial awaiting assessment&lt;/p&gt;" WIDTH="267"/></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>